[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 169
1. Yildirim H, Metintas M, Entok E, Ak G, Ak I, Dundar E, Erginel S: Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study. J Thorac Oncol; 2009 Dec;4(12):1480-4
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical value of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiation of malignant mesothelioma from asbestos-related benign pleural disease: an observational pilot study.
  • In this pilot study, we investigate the role of 18F-FDG positron emission tomography/computed tomography (PET/CT) for differentiating asbestos-related benign pleural disease from malignant mesothelioma.
  • MATERIALS AND METHODS: The study population comprised 31 consecutive patients (17 malignant mesotheliomas, nine benign asbestos pleurisies, and five diffuse pleural fibrosis) with a mean age of 61 years between January 2006 and December 2008.
  • Thoracoscopy or image-guided pleural needle biopsy were systematically performed to reveal pathologic diagnosis and/or clinical follow-up for at least 3 years for presence or absence of malignant pleural effusion.
  • ROCs analyses for standardized uptake value (SUV) adjusted to body weight were calculated between benign and malignant pleural diseases.
  • RESULTS: 18F-FDG PET/CT imaging correctly detected the presence of malignancies in 15 of 17 patients with malignant mesothelioma for sensitivity, specificity, and overall accuracy of 88.2%, 92.9%, and 90.3%, respectively.
  • The mean SUV values were 6.5 +/- 3.4 for malignant mesothelioma cases and 0.8 +/- 0.6 for benign pleural diseases (p < 0.001).
  • CONCLUSION: Preliminary results of this trial provide evidence that 18F-FDG PET/CT imaging is a highly accurate and reliable noninvasive test to decide for further investigation of differentiating malignant mesothelioma from benign pleural disease.
  • [MeSH-major] Asbestos / adverse effects. Fluorodeoxyglucose F18. Mesothelioma / radionuclide imaging. Pleural Diseases / radionuclide imaging. Pleural Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19875971.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 1332-21-4 / Asbestos
  •  go-up   go-down


2. Lee KH, Yoon HS, Choi SJ, Kang D: Asbestos exposure and malignant mesothelioma in Korea. Asian Pac J Cancer Prev; 2009 Oct-Dec;10(4):707-10
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asbestos exposure and malignant mesothelioma in Korea.
  • Although importation of asbestos to Korea has decreased, there are growing concerns of its hazardous effects.
  • This paper describes the use and occupational exposure to asbestos, and the incidence and mortality of malignant mesotheliomas in Korea.
  • Asbestos raw material imports from other countries peaked between 1990 and 1995, but importation of asbestos-containing and -processed materials has steadily increased until now.
  • The average airborne asbestos concentration was lower than from other countries and steadily decreased during the study period.
  • The number of malignant mesothelioma cases in Korea was 48 in 1998, 39 in 1999, 45 in 2000, 38 in 2001, and 46 in 2002.
  • There were 334 deaths due to malignant mesothelioma and an average of 30.4 deaths per year between 1996 and 2006.
  • The number of deaths attributed to malignant mesothelioma ranged from 16 cases in 1999 to 57 cases in 2006.
  • The magnitude of asbestos-related health problems in Korea has been underestimated due to under-diagnosis, incomplete reports, and shorter duration of exposure.
  • A nationwide surveillance system for asbestos exposure and malignant mesothelioma should therefore be implemented.
  • [MeSH-major] Asbestos / adverse effects. Mesothelioma / etiology. Occupational Exposure / adverse effects. Pleural Neoplasms / etiology


3. Bianchi C, Bianchi T: Malignant mesothelioma: global incidence and relationship with asbestos. Ind Health; 2007 Jun;45(3):379-87
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma: global incidence and relationship with asbestos.
  • Mesothelioma incidence varies markedly from one country to another.
  • A lot of data indicate a relationship between mesothelioma and asbestos.
  • The hot areas for mesothelioma exactly correspond to the sites of industries with high asbestos use, such as shipbuilding and asbestos-cement industry.
  • However, in many countries with high asbestos consumption, mesothelioma incidence is low.
  • The latency periods elapsing between first exposure to asbestos and development of mesothelioma are mostly longer than 40 yr.
  • An inverse relationship exists between intensity of asbestos exposure and length of the latency period.
  • Mesothelioma generally develops after long-time exposures to asbestos.
  • Possible co-factors in the pathogenesis of asbestos-related mesothelioma include genetic predisposition, diets poor in fruit and vegetables, viruses, immune impairment, recurrent serosal inflammation.
  • The study of co-morbidity in mesothelioma could give an insight into the pathogenesis of the tumor.
  • While a levelling-off in mesothelioma incidence has been registered in some countries, a worsening of the epidemic is predictable in large parts of the world.
  • [MeSH-major] Asbestos / toxicity. Developed Countries / statistics & numerical data. Environmental Exposure / adverse effects. Global Health. Mesothelioma / epidemiology


Advertisement
4. Tsou MT, Luo JC: Porcelain factory worker with asbestos-related mesothelioma. J Formos Med Assoc; 2009 Oct;108(10):819-25
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Porcelain factory worker with asbestos-related mesothelioma.
  • Malignant mesothelioma is a rare tumor among the general population, but for people exposed to asbestos, the lifetime risk is high.
  • A chest X-ray revealed right-side pleural effusion; however, pleural biopsy from drainage treatment confirmed a diagnosis of malignant mesothelioma.
  • The specific characteristics of his work, making asbestos wallboards and gaskets, entailed working in high-temperature conditions with a high fine-particle content in the atmosphere.
  • The high working temperature caused asbestos debris and dust to fall down regularly from the wallboards, however, it was not until recently that the patient had started to wear personal protection.
  • Asbestos is a significant source of hazardous exposure in old buildings, and this case serves as a reminder of the importance of asbestos-related exposure history, which facilitated the correct diagnosis of pulmonary malignant mesothelioma.
  • Asbestos-containing materials that are now banned or regulated are still present in older buildings and remain an exposure hazard; they continue to be a serious health concern in many countries.

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Formos Med Assoc. 2010 May;109(5):389 [20497872.001]
  • (PMID = 19864204.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Singapore
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


5. Dianzani I, Gibello L, Biava A, Giordano M, Bertolotti M, Betti M, Ferrante D, Guarrera S, Betta GP, Mirabelli D, Matullo G, Magnani C: Polymorphisms in DNA repair genes as risk factors for asbestos-related malignant mesothelioma in a general population study. Mutat Res; 2006 Jul 25;599(1-2):124-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in DNA repair genes as risk factors for asbestos-related malignant mesothelioma in a general population study.
  • This paper describes the results of a case-control epidemiological study designed to determine the genotypes of four of these genes in persons exposed to a single genotoxic factor, i.e. asbestos, who had or had not developed malignant mesothelioma (MM).
  • Our working hypothesis was that an imperfect DNA repair, as revealed by subtle polymorphic variants, could reduce protection against the chronic DNA insult provoked by asbestos and eventually result in mutagenesis and cancer.
  • XRCC1-R399Q-NCBI SNP, XRCC1-R194W, XRCC3-T241M, XRCC3-IVS6-14, XPD-K751Q, XPD-D312N, OGG1-S326C) were investigated in 81 patients and 110 age and sex-matched controls, all residents at Casale Monferrato, a Piedmontese town highly exposed to asbestos pollution.
  • This is the first report of an association between polymorphisms in DNA repair genes and asbestos-associated MM.
  • [MeSH-major] Asbestos / adverse effects. DNA Repair / genetics. Mesothelioma / etiology. Mesothelioma / genetics. Pleural Neoplasms / etiology. Pleural Neoplasms / genetics. Polymorphism, Genetic

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16564556.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / X-ray repair cross complementing protein 1; 0 / X-ray repair cross complementing protein 3; 1332-21-4 / Asbestos; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / oxoguanine glycosylase 1, human; EC 3.6.4.12 / Xeroderma Pigmentosum Group D Protein; EC 5.99.- / ERCC2 protein, human
  •  go-up   go-down


6. Marinaccio A, Binazzi A, Cauzillo G, Chellini E, De Zotti R, Gennaro V, Menegozzo M, Mensi C, Merler E, Mirabelli D, Musti M, Pannelli F, Romanelli A, Scarselli A, Tosi S, Tumino R, Nesti M, Gruppo di lavoro ReNaM: [Epidemiological surveillance of malignant mesothelioma cases in Italy: incidence and asbestos exposure figures by the Italian mesothelioma registry (ReNaM)]. Epidemiol Prev; 2007 Jul-Aug;31(4 Suppl 1):23-6
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiological surveillance of malignant mesothelioma cases in Italy: incidence and asbestos exposure figures by the Italian mesothelioma registry (ReNaM)].
  • The Study describes the epidemiological surveillance of mesothelioma cases carried out by the Italian mesothelioma register (ReNaM).
  • A Regional Operating Centre (COR) is present in nearly all Italian regions (17 out of 20) and it collects malignant mesothelioma cases and investigate the modalities of asbestos exposure by using a structured questionnaire.
  • The register produces malignant mesothelioma incidence measures and analyses of the modalities of the asbestos exposure.
  • The standardized incidence rate of malignant mesothelioma in 2001 was 2.98 (in 100,000 inhabitants) among men and 0.98 among women; a professional (certain, probable, possible) exposure has been detected in 67.4% of defined cases.
  • In addition to the conventional sectors (shipbuilding, railways repair and demolition, asbestos-cement production), also textile, building, transport, chemical and glass industries, petroleum and sugar refineries, electricity production and distribution plants are getting involved.
  • Despite the absence of some regions completing the national coverage and the non homogeneity in collecting and coding data, the epidemiological surveillance of malignant mesothelioma carried out by ReNaM is an important tool for the scientific knowledge and the prevention of asbestos-related diseases.
  • [MeSH-major] Asbestos / adverse effects. Mesothelioma / epidemiology. Mesothelioma / etiology. Occupational Diseases / epidemiology. Occupational Diseases / etiology. Occupational Exposure / adverse effects. Pleural Neoplasms / epidemiology. Pleural Neoplasms / etiology


7. Munkholm-Larsen S, Cao CQ, Yan TD: Malignant peritoneal mesothelioma. World J Gastrointest Surg; 2009 Nov 30;1(1):38-48
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peritoneal mesothelioma.
  • Malignant mesothelioma is a highly aggressive neoplasm.
  • The incidence of malignant mesothelioma is increasing worldwide.
  • Diffuse malignant peritoneal mesothelioma (DMPM) represents one-fourth of all mesotheliomas.
  • Association of asbestos exposure with DMPM has been observed, especially in males.
  • This remarkable improvement in survival has prompted new search into the medical science related to DMPM, a disease previously ignored as uninteresting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160794.001).
  • [ISSN] 1948-9366
  • [Journal-full-title] World journal of gastrointestinal surgery
  • [ISO-abbreviation] World J Gastrointest Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999110
  • [Keywords] NOTNLM ; Asbestos / Cisplatin / Cytoreductive surgery / Doxorubicin / Intraperitoneal chemotherapy / Mesothelin / Pemetrexed / Peritoneal mesothelioma / Peritonectomy
  •  go-up   go-down


8. Ikegami Y, Kawai N, Tozawa K, Hayashi Y, Kohri K: Malignant mesothelioma of the tunica vaginalis testis related to recent asbestos. Int J Urol; 2008 Jun;15(6):560-1
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma of the tunica vaginalis testis related to recent asbestos.
  • We report an extremely rare case of malignant mesothelioma in the tunica vaginalis testis.
  • The histopathological diagnosis was malignant mesothelioma, and he died 26 months later from multiple metastases.
  • Asbestos may be a significant contributor to malignant mesothelioma in Japan.
  • There have been 46 cases reported in urology departments in this country of the related symptoms, but only two of these have been clearly attributable to asbestos, which may be due to the investigations being insufficient to obtain a definitive diagnosis.
  • [MeSH-major] Asbestos / adverse effects. Mesothelioma / etiology. Testicular Neoplasms / etiology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Urol. 2008 Aug;15(8):755
  • (PMID = 18489651.001).
  • [ISSN] 1442-2042
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


9. Betti M, Neri M, Ferrante D, Landi S, Biava A, Gemignani F, Bertolotti M, Mirabelli D, Padoan M, Ugolini D, Botta M, Bonassi S, Magnani C, Dianzani I: Pooled analysis of NAT2 genotypes as risk factors for asbestos-related malignant mesothelioma. Int J Hyg Environ Health; 2009 May;212(3):322-9
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pooled analysis of NAT2 genotypes as risk factors for asbestos-related malignant mesothelioma.
  • Malignant mesothelioma (MM) is a rare and aggressive tumor of the pleura.
  • The most important causal factor for the development of MM is occupational exposure to asbestos.
  • To ascertain the role of NAT2 genotype, we performed a study on 252 MM patients and 262 controls recruited in two Northern Italy areas that were characterized by high asbestos exposure, due to intense industrial activities (an asbestos cement factory in Casale Monferrato, mainly shipyards and refineries in Liguria).
  • NAT2 fast acetylator genotypes showed an increased OR, although not statistically significant, both in asbestos-exposed subjects (OR=1.47; 95% CI=0.96-2.26) and in the entire population (OR=1.38; 95% CI=0.93-2.04).
  • [MeSH-major] Arylamine N-Acetyltransferase / genetics. Asbestos / adverse effects. Carcinogens. Genetic Predisposition to Disease. Mesothelioma / genetics. Pleural Neoplasms / genetics. Polymorphism, Genetic

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18838334.001).
  • [ISSN] 1618-131X
  • [Journal-full-title] International journal of hygiene and environmental health
  • [ISO-abbreviation] Int J Hyg Environ Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Carcinogens; 1332-21-4 / Asbestos; EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / NAT2 protein, human
  •  go-up   go-down


10. Marinaccio A, Binazzi A, Cauzillo G, Cavone D, Zotti RD, Ferrante P, Gennaro V, Gorini G, Menegozzo M, Mensi C, Merler E, Mirabelli D, Montanaro F, Musti M, Pannelli F, Romanelli A, Scarselli A, Tumino R, Italian Mesothelioma Register (ReNaM) Working Group: Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. Eur J Cancer; 2007 Dec;43(18):2722-8
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register.
  • Italy was an important producer of raw asbestos until 1992 (when it was banned) and it is now experiencing severe public health consequences due to large-scale industrial use of asbestos in shipbuilding and repair, asbestos-cement production, railways, buildings, chemicals and many other industrial sectors.
  • Latency of malignant mesothelioma generally shows a large variability and the relationship with the modality of asbestos exposure is still not fully clarified.
  • We present an analysis of latency period among the case list collected by the Italian mesothelioma register (ReNaM) in the period of diagnosis 1993-2001 (2544 malignant mesothelioma (MM) cases with asbestos exposure history).
  • The role of diagnostic confidence level, the morphology of the tumour and the modalities of asbestos exposure were verified in a regression multivariate model.
  • [MeSH-major] Asbestos / toxicity. Environmental Exposure / adverse effects. Heart Neoplasms / epidemiology. Mesothelioma / epidemiology. Peritoneal Neoplasms / epidemiology. Pleural Neoplasms / epidemiology. Testicular Neoplasms / epidemiology


11. Giacomini S, Mensi C, Sieno C, Riboldi L: [Asbestos-related malignant mesothelioma of the pleura in a young person]. Med Lav; 2009 Sep-Oct;100(5):396
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Asbestos-related malignant mesothelioma of the pleura in a young person].
  • [MeSH-major] Asbestos / adverse effects. Carcinogens. Mesothelioma / etiology. Occupational Diseases / etiology. Occupational Exposure / adverse effects. Pleural Neoplasms / etiology


12. Partemi S, De Giorgio F: Medico-legal aspects of mesothelioma. Ann Ital Chir; 2007 Sep-Oct;78(5):401-3
MedlinePlus Health Information. consumer health - Occupational Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medico-legal aspects of mesothelioma.
  • The Authors, reviewing the Literature on asbestos-related Malignant Mesothelioma (MM), found that because of its very peculiar characteristics, the causal link between professional asbestos exposure and the development of this tumour is very difficult to define in respect to: diagnosis, causal link and individuation of possible culpable conducts.
  • In fact it is sufficient, that asbestos-related lesions are ascertained in individuals who are or were exposed at any time of their professional life to the risk of inhaling asbestos fibres.
  • [MeSH-major] Mesothelioma. Occupational Diseases. Workers' Compensation / legislation & jurisprudence

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18338548.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 15
  •  go-up   go-down


13. Meirelles GS, Kavakama JI, Jasinowodolinski D, Nery LE, Terra-Filho M, Rodrigues RT, Neder JA, Bagatin E, D'ippolito G: [Asbestos-related pleuropulmonary diseases: pictorial essay]. Rev Port Pneumol; 2005 Sep-Oct;11(5):477-85
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Asbestos-related pleuropulmonary diseases: pictorial essay].
  • [Transliterated title] Alterações pleurais e parenquimatosas relacionadas com a exposição ao asbestos: ensaio pictórico.
  • Pleural and pulmonary asbestos-related diseases range from benign conditions, like pleural effusion and pleural plaques, to some neoplasias, such as lung cancer and malignant mesothelioma.
  • Pleural effusion is the earliest finding after asbestos exposure, but the imaging findings are not specific.
  • Asbestosis is the pulmonary fibrosis due to asbestos.
  • Rounded atelectasis is a peripheral lung collapse in these individuals, generally related to pleural disease.
  • Some neoplasias, like lung carcinoma and pleural mesothelioma, are more prevalent in asbestos-exposed subjects.
  • The aim of this essay is to illustrate the main imaging findings of asbestos-related diseases.
  • [MeSH-major] Asbestos / adverse effects. Asbestosis / radiography. Pleural Diseases / etiology. Pleural Diseases / radiography

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16288346.001).
  • [ISSN] 0873-2159
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Portugal
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  • [Number-of-references] 38
  •  go-up   go-down


14. Busacca S, Germano S, De Cecco L, Rinaldi M, Comoglio F, Favero F, Murer B, Mutti L, Pierotti M, Gaudino G: MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am J Respir Cell Mol Biol; 2010 Mar;42(3):312-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications.
  • Human malignant mesothelioma is an asbestos-related cancer, with poor prognosis and low median survival.
  • Here we report, for the first time, a cross-evaluation of miRNA expression in mesothelioma (MPP-89, REN) and human mesothelial cells (HMC-telomerase reverse transcriptase).
  • Microarray profiling, confirmed by real-time quantitative RT-PCR, revealed a differential expression of miRNAs between mesothelioma and mesothelial cells.
  • Several predicted genes belong to terms of Gene Ontology (GO) that are associated with the development and progression of mesothelioma.
  • This suggests that miRNAs may be key players in mesothelioma oncogenesis.
  • We further investigated miRNA expression on a panel of 24 mesothelioma specimens, representative of the three histotypes (epithelioid, biphasic, and sarcomatoid), by quantitative RT-PCR.
  • Our preliminary analysis points at miRNAs as potential diagnostic and prognostic markers of mesothelioma, and suggests novel tools for the therapy of this malignancy.
  • [MeSH-major] Gene Expression Profiling. Mesothelioma / diagnosis. Mesothelioma / genetics. MicroRNAs / genetics

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19502386.001).
  • [ISSN] 1535-4989
  • [Journal-full-title] American journal of respiratory cell and molecular biology
  • [ISO-abbreviation] Am. J. Respir. Cell Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MicroRNAs
  •  go-up   go-down


15. Kurimoto R, Kishimoto T, Nagai Y, Takazawa H, Sakaue N, Shinohara Y, Hiroshima K: Malignant peritoneal mesothelioma: quantitative analysis of asbestos burden. Pathol Int; 2009 Nov;59(11):823-7
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant peritoneal mesothelioma: quantitative analysis of asbestos burden.
  • Malignant mesotheliomas develop commonly in the pleural cavity and rarely arise in the peritoneal cavity.
  • It is well established that asbestos exposure is related to malignant pleural mesothelioma, but the asbestos burden in the abdominal cavity in patients with malignant peritoneal mesothelioma has not been well studied.
  • The purpose of the present study was therefore to report on an autopsy case of malignant peritoneal mesothelioma with quantitative analysis of the asbestos burden in tissues from the pleura and organs in the abdominal cavity.
  • The patient was a 67-year-old man with a history of asbestos exposure.
  • This patient was diagnosed as having malignant peritoneal epithelioid mesothelioma.
  • The number of asbestos fibers was >10,000/g dry tissue in all samples examined except in the small intestine.
  • The number of asbestos fibers in the stomach was 53,000/g, which was higher than that in a control asbestosis subject.
  • The existence of numerous asbestos fibers found in the abdominal cavity suggests that asbestos stimuli are related to the tumorigenesis of malignant peritoneal mesothelioma.
  • [MeSH-major] Asbestos / adverse effects. Asbestos / analysis. Asbestosis / pathology. Mesothelioma / etiology. Peritoneal Neoplasms / etiology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19883435.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Mineral Fibers; 1332-21-4 / Asbestos
  •  go-up   go-down


16. Wheatley-Price P, Yang B, Patel D, Ma C, Xu W, Leighl N, Feld R, Cho B, De Perrot M, Liu G: Mesothelin as a marker of response in malignant pleural mesothelioma. J Clin Oncol; 2009 May 20;27(15_suppl):7581

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelin as a marker of response in malignant pleural mesothelioma.
  • : 7581 Background: Malignant pleural mesothelioma (MPM) is a rare malignancy related to asbestos exposure.
  • Soluble mesothelin related peptide (sMRP) can distinguish between MPM and benign pleural disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963378.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Hida T, Ogawa S, Park J, Park J, Shimizu J, Horio Y, Yoshida K, Sekido Y: Chemosensitivity of newly established human malignant pleural mesothelioma cells: Significant growth inhibition by amrubicin, a novel 9-aminoanthracycline, or cyclooxygenase 2 inhibitor. J Clin Oncol; 2009 May 20;27(15_suppl):e19060

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemosensitivity of newly established human malignant pleural mesothelioma cells: Significant growth inhibition by amrubicin, a novel 9-aminoanthracycline, or cyclooxygenase 2 inhibitor.
  • : e19060 Background: Malignant pleural mesothelioma is asbestos-related malignancy that is highly resistant to current therapeutic modalities.
  • Survival of patients with malignant mesothelioma is very poor, especially in advanced stage, regardless of a recent advancement of chemotherapeutical modalities of combination with cisplatin and antifolate.
  • METHODS: Eleven cell lines derived from malignant mesothelioma were established in our laboratory.
  • RESULTS: Anti-cancer agents, cisplatin, vinorelbine, gemcitabine, gefitinib, or erlotinib, showed little growth inhibition, and pemetrexed and irinotecan showed modest growth inhibition in malignant mesothelioma cells, whereas amrubicin-13-OH showed strong growth inhibition.
  • Cyclooxygenase 2 inhibitors inhibit proliferation of malignant mesothelioma cells in a dose-dependent manner: modest growth inhibition at clinically achievable low concentrations and complete growth inhibition at clinically achievable high concentrations by intrapleural instillation.
  • CONCLUSIONS: Our study suggests that amrubicin can inhibit proliferation of malignant mesothelioma cells.
  • In addition, the use of a cyclooxygenase 2 inhibitor may be a promising therapeutic approach in the treatment of mesothelioma, because previous studies indicated the presence of increased cyclooxygenase 2 expression in malignant mesothelioma, which is notoriously resistant to chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962139.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Greillier L, Astoul P: Mesothelioma and asbestos-related pleural diseases. Respiration; 2008;76(1):1-15
MedlinePlus Health Information. consumer health - Pleural Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelioma and asbestos-related pleural diseases.
  • At present, the use of asbestos is not regulated at a worldwide scale.
  • Moreover, there is a latency period between asbestos exposure and the manifestations of asbestos-related diseases.
  • Consequently, pulmonologists are still dealing with consequences of asbestos exposure, which mainly occur at the pleural surface.
  • The aim of this review is to provide an overview of asbestos-related pleural diseases.
  • We summarized the most relevant data for the diagnosis and the management of benign asbestos pleural effusions, pleural plaques, diffuse pleural thickening and rounded atelectasis.
  • Special attention is dedicated to malignant pleural mesothelioma, given the challenging issues of this disease, the recent advances in its management and the dynamism of research in this area.
  • [MeSH-major] Asbestosis. Mesothelioma. Pleural Diseases. Pleural Neoplasms

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel.
  • (PMID = 18583923.001).
  • [ISSN] 1423-0356
  • [Journal-full-title] Respiration; international review of thoracic diseases
  • [ISO-abbreviation] Respiration
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 189
  •  go-up   go-down


19. Proietti L, Spicuzza L, Di Maria A, Polosa R, Sebastian Torres E, Asero V, Di Maria GU: Non-occupational malignant pleural mesothelioma due to asbestos and non-asbestos fibres. Monaldi Arch Chest Dis; 2006 Dec;65(4):210-6
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-occupational malignant pleural mesothelioma due to asbestos and non-asbestos fibres.
  • BACKGROUND AND AIM: The occurrence of malignant pleural mesothelioma (MPM) has been reported among population groups with no documented professional exposure to asbestos fibres living in different geographic areas.
  • This paper reviews existing data related to non occupational MPM including its occurrence in the province of Catania (Sicily, Italy).
  • METHODS: An electronic search of literature related to non occupational MPM was performed including the year 2005.
  • RESULTS: Non occupational MPM in subjects living in areas contaminated by a variety of asbestos and non asbestos fibres has been well documented through a number of epidemiologic studies including cases series, case-control studies, and a cohort study.
  • CONCLUSION: It is likely that genetic predisposition and non-occupational exposure to low doses of asbestos and asbestos-like fibres may concur to the development of malignant mesothelioma.

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17393666.001).
  • [ISSN] 1122-0643
  • [Journal-full-title] Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace
  • [ISO-abbreviation] Monaldi Arch Chest Dis
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Mineral Fibers; 1332-21-4 / Asbestos
  • [Number-of-references] 86
  •  go-up   go-down


20. Mirabelli D, Cavone D, Merler E, Gennaro V, Romanelli A, Mensi C, Chellini E, Nicita C, Marinaccio A, Magnani C, Musti M: Non-occupational exposure to asbestos and malignant mesothelioma in the Italian National Registry of Mesotheliomas. Occup Environ Med; 2010 Nov;67(11):792-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-occupational exposure to asbestos and malignant mesothelioma in the Italian National Registry of Mesotheliomas.
  • BACKGROUND: Malignant mesotheliomas are strictly related to asbestos, but in a proportion of cases no exposure can be recalled.
  • METHODS: To assess the role of non-occupational exposures in causing malignant mesotheliomas in Italy, the exposures of cases registered by the national mesothelioma registry (ReNaM) were examined.
  • RESULTS: From 1993 to 2001 ReNaM registered 5173 malignant mesothelioma cases, and exposures were assessed in 3552 of them.
  • 144 and 150 cases with exposures limited to environmental (living in the neighbourhood of an industrial or natural source of asbestos) or familial (living with a person occupationally exposed to asbestos) circumstances, respectively, were identified, accounting for 8.3% of all cases.
  • CONCLUSIONS: Geographical variations in the proportion of cases due to non-occupational exposures may be explained by the past distribution of asbestos-using industries.
  • [MeSH-major] Asbestos / toxicity. Environmental Exposure / adverse effects. Mesothelioma / etiology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20959396.001).
  • [ISSN] 1470-7926
  • [Journal-full-title] Occupational and environmental medicine
  • [ISO-abbreviation] Occup Environ Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


21. Creaney J, Olsen NJ, Brims F, Dick IM, Musk AW, de Klerk NH, Skates SJ, Robinson BW: Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. Cancer Epidemiol Biomarkers Prev; 2010 Sep;19(9):2238-46
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma.
  • BACKGROUND: Malignant mesothelioma is an aggressive, almost uniformly fatal tumor, primarily caused by exposure to asbestos.
  • Since the recent discovery that serum mesothelin is a sensitive and highly specific biomarker for mesothelioma, one of the key issues raised is whether mesothelin levels represent a useful screening test for asbestos-exposed at-risk individuals.
  • In this study, soluble mesothelin was determined in sequential serum samples collected from asbestos-exposed individuals before the development of mesothelioma.
  • METHODS: Archival serum samples from 106 individuals who developed mesothelioma, 99 asbestos-exposed individuals from the Wittenoom Cancer Surveillance Program, and 109 non-asbestos-exposed individuals from the Busselton Health Survey were identified.
  • RESULTS: Longitudinal mesothelin levels determined in healthy asbestos-exposed individuals over a period of 4 years were stable (Pearson's r = 0.96; P < 0.0001).
  • There was no correlation between mesothelin concentration and cumulative asbestos exposure.
  • Mesothelin concentrations were greater than the threshold value of 2.5 nmol/L in the penultimate serum sample before the diagnosis of mesothelioma in 17 of 106 people.
  • CONCLUSION: In a population with a high pretest probability of developing mesothelioma, the serum biomarker mesothelin is elevated in absolute terms in 15% and in relative terms in 40% of the group.
  • [MeSH-major] Asbestos / adverse effects. Biomarkers, Tumor / blood. Membrane Glycoproteins / blood. Mesothelioma / blood. Mesothelioma / etiology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c)2010 AACR.
  • (PMID = 20651076.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 1332-21-4 / Asbestos
  •  go-up   go-down


22. Takemura Y, Satoh M, Satoh K, Hamada H, Sekido Y, Kubota S: High dose of ascorbic acid induces cell death in mesothelioma cells. Biochem Biophys Res Commun; 2010 Apr 2;394(2):249-53
Hazardous Substances Data Bank. L-Ascorbic Acid .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose of ascorbic acid induces cell death in mesothelioma cells.
  • Malignant mesothelioma is an asbestos-related fatal disease with no effective cure.
  • We studied whether high dose of ascorbic acid induced cell death of four human mesothelioma cell lines.
  • High dose of ascorbic acid induced cell death of all mesothelioma cell lines in a dose-dependent manner.
  • In vivo experiment, intravenous administration of ascorbic acid significantly decreased the growth rate of mesothelioma tumor inoculated in mice.
  • These data suggest that ascorbic acid may have benefits for patients with mesothelioma.
  • [MeSH-major] Apoptosis. Ascorbic Acid / administration & dosage. Mesothelioma / drug therapy

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Vitamin C.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20171954.001).
  • [ISSN] 1090-2104
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Reactive Oxygen Species; PQ6CK8PD0R / Ascorbic Acid
  •  go-up   go-down


23. Scripcariu V, Dajbog E, Lefter L, Ferariu D, Pricop A, Grigoraş M, Dragomir C: [Malignant peritoneal mesothelioma]. Chirurgia (Bucur); 2006 Nov-Dec;101(6):641-6
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant peritoneal mesothelioma].
  • Mesothelioma is a neoplasm originating from the mesothelial surface lining cells of the serous human cavities.
  • Asbestos has been widely used in industry.
  • A causal relationship between asbestos exposure and pleural, peritoneal and pericardial malign mesothelioma was suggested, the risk of cancer being correlated to cumulate exposure.
  • Studies from National Cancer Institute, USA, show that the malignant mesothelioma is a rare and aggressive asbestos related malignancy.
  • This paper presents the case of a 59 year old patient with malignant peritoneal mesothelioma who worked almost 40 years as an electrician, exposed to asbestos fibers.
  • [MeSH-major] Asbestos / adverse effects. Mesothelioma / etiology. Occupational Diseases / etiology. Peritoneal Neoplasms / etiology


24. Bianchi C, Bianchi T: Susceptibility and resistance in the genesis of asbestos-related mesothelioma. Indian J Occup Environ Med; 2008 Aug;12(2):57-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Susceptibility and resistance in the genesis of asbestos-related mesothelioma.
  • Asbestos is the principal agent in the etiology of malignant mesothelioma.
  • However, a small proportion of people exposed to asbestos develop mesothelioma.
  • A genetic susceptibility is suggested by the occurrence of more mesothelioma cases among blood-related members of a single family.
  • Such an occurrence reached about 4% in a large mesothelioma series.
  • In some studies, mesothelioma patients showed higher prevalences of additional malignancies when compared with controls.
  • This indicates a particular vulnerability to cancer in people with mesothelioma.
  • Not rarely, very old persons heavily exposed to asbestos remain free from asbestos-related cancer, a fact indicating an absolute resistance to the oncogenic effects of asbestos.
  • A relative resistance may be recognized in people severely exposed to asbestos who develop mesothelioma only after 60 years or more since the onset of the exposure.
  • The long survivals, rarely observed among mesothelioma patients, have been attributed to a high efficiency of immune mechanisms.
  • The natural history of mesothelioma shows that a resistance to the oncogenic effects of asbestos does exist.
  • To strengthen the defence mechanisms may represent a way for preventing mesothelioma among people exposed to asbestos.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Ind Med. 2007 May;50(5):357-69 [17407142.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1432-8 [17315168.001]
  • [Cites] Lancet. 2007 Mar 10;369(9564):844-9 [17350453.001]
  • [Cites] Respir Med. 2007 Mar;101(3):503-9 [16919927.001]
  • [Cites] Chest. 2007 Feb;131(2):376-82 [17296636.001]
  • [Cites] Ann Thorac Surg. 2007 Jan;83(1):314-5 [17184695.001]
  • [Cites] Thorax. 2006 Oct;61(10):916-7 [17008483.001]
  • [Cites] Mutat Res. 2006 Jul 25;599(1-2):124-34 [16564556.001]
  • [Cites] Med Lav. 2005 Jul-Aug;96(4):287-303 [16457426.001]
  • [Cites] Mutat Res. 2005 Dec 30;592(1-2):36-44 [15993904.001]
  • [Cites] Chest. 1993 Apr;103(4):1268-9 [8131480.001]
  • [Cites] Ind Health. 2004 Apr;42(2):235-9 [15128174.001]
  • [Cites] Transplantation. 2003 Nov 27;76(10):1448-51 [14657684.001]
  • [Cites] Lung Cancer. 2003 Oct;42(1):63-8 [14512189.001]
  • [Cites] Ann Occup Hyg. 2003 Aug;47(6):485-92 [12890657.001]
  • [Cites] Tumori. 2002 Jan-Feb;88(1):1-9 [12004841.001]
  • [Cites] Ind Health. 2001 Apr;39(2):161-7 [11341546.001]
  • [Cites] Ind Health. 2000 Jul;38(3):301-8 [10943078.001]
  • [Cites] Ann Oncol. 1999;10 Suppl 5:S87-90 [10582147.001]
  • [Cites] Mutat Res. 2008 Mar-Apr;658(3):162-71 [17904414.001]
  • [Cites] Int J Occup Environ Health. 2007 Oct-Dec;13(4):398-403 [18085053.001]
  • [Cites] Med Lav. 2007 Sep-Oct;98(5):374-80 [17907531.001]
  • [Cites] Bull Cancer. 2007 Jul;94(7):705-10 [17723954.001]
  • [Cites] Lung Cancer. 2007 Sep;57(3):407-9 [17400330.001]
  • [Cites] Ind Health. 2007 Jun;45(3):379-87 [17634686.001]
  • [Cites] Tumori. 2007 Jan-Feb;93(1):19-22 [17455866.001]
  • (PMID = 20040979.001).
  • [ISSN] 1998-3670
  • [Journal-full-title] Indian journal of occupational and environmental medicine
  • [ISO-abbreviation] Indian J Occup Environ Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2796755
  • [Keywords] NOTNLM ; Asbestos / familial cancer / host factors / immune impairment / mesothelioma / resistance / susceptibility
  •  go-up   go-down


25. Tsuzuki T, Ninomiya H, Natori Y, Ishikawa Y: Coalescent pleural malignant mesothelioma and adenocarcinoma of the lung, involving only minor asbestos exposure. Pathol Int; 2008 Jul;58(7):451-5
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coalescent pleural malignant mesothelioma and adenocarcinoma of the lung, involving only minor asbestos exposure.
  • Coexistence of pulmonary adenocarcinoma and pleural malignant mesothelioma is extremely rare, although both are asbestos-related.
  • Herein is presented a rare case of coalescent lung tumor made up of a malignant mesothelioma and a pulmonary adenocarcinoma in a 62-year-old Japanese man, a high-school teacher with only minor asbestos exposure.
  • They were confirmed to be malignant mesothelioma on histopathology of paraffin section.
  • The former was positive for adenocarcinoma markers such as CEA, Ber-EP4, PE-10, thyroid transcription factor-1 and Napsin A, and negative for mesothelial markers including calretinin, D2-40, WT-1 and HBME, while the latter was the opposite, resulting in a diagnosis of coalescing malignant mesothelioma and adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Asbestos / adverse effects. Lung Neoplasms / pathology. Mesothelioma / pathology. Neoplasms, Multiple Primary / pathology. Pleural Neoplasms / pathology


26. Neri M, Taioli E, Filiberti R, Paolo Ivaldi G, Aldo Canessa P, Verna A, Marroni P, Puntoni R, Hirvonen A, Garte S: Metabolic genotypes as modulators of asbestos-related pleural malignant mesothelioma risk: a comparison of Finnish and Italian populations. Int J Hyg Environ Health; 2006 Jul;209(4):393-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic genotypes as modulators of asbestos-related pleural malignant mesothelioma risk: a comparison of Finnish and Italian populations.
  • The role of CYP1A1, GSTM1, GSTT1, EPHX1, and NAT2 genotypes in susceptibility to malignant mesothelioma (MM) was compared in two case-control studies, previously conducted in two countries where different types of asbestos fibers have been used [Hirvonen et al., 1995.
  • Inherited GSTM1 and NAT2 defects as concurrent risk modifiers in asbestos-related human malignant mesothelioma.
  • Glutathione S-Transferase and N-Acetyltransferase genotypes and asbestos-associated pulmonary disorders. J. Natl.
  • Pleural malignant mesothelioma, genetic susceptibility and asbestos exposure. Mutat. Res. 592, 36-44].
  • Fifty-seven asbestos-exposed MM patients and 255 controls were recruited in Italy, 48 cases and 121 controls in Finland.
  • The opposite results obtained in Finland and Italy may be ascribed to random chance, but a role may be hypothesized for the fact that different types of asbestos have been used in the two countries.
  • [MeSH-major] Asbestos / toxicity. Genetic Predisposition to Disease. Mesothelioma / genetics. Pleural Neoplasms / genetics

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16697254.001).
  • [ISSN] 1438-4639
  • [Journal-full-title] International journal of hygiene and environmental health
  • [ISO-abbreviation] Int J Hyg Environ Health
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 1332-21-4 / Asbestos; EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / NAT2 protein, human; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1; EC 3.3.2.- / Epoxide Hydrolases
  •  go-up   go-down


27. Kanceljak-Macan B: [Immunological aspects of asbestos-related diseases]. Arh Hig Rada Toksikol; 2009 Nov;60 Suppl:45-50
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunological aspects of asbestos-related diseases].
  • Asbestos is a generic name for a group of silicate minerals.
  • Exposure to asbestos may cause asbestos-related non-malignant diseases of the lung and pleura, including asbestosis, pleural plaques, diffuse pleural fibrosis, small airway disease, and malignant diseases such as lung cancer and malignant mesothelioma.
  • Inhaled asbestos fibres deposit in the distal regions of the respiratory system where they interact with epithelial cells and alveolar macrophages, and trigger active immunological response which leads to a slowly progressing lung fibrosis.
  • Asbestos may affect immunocompetent cells and induce malignant transformation of mesothelial cells.
  • It is still not clear whether asbestos causes mesothelioma directly or indirectly.
  • There is a general opinion that malignant mesothelioma is a complex tumour that results from the accumulation of multiple genetic alterations over many years.
  • There is no specific antibody for malignant mesothelioma as yet which could act as a single diagnostic tool.
  • Recent studies have demonstrated that asbestos acts on peripheral T cells as superantigen and that in malignant mesothelioma patients there is an overexpression of the Bcl-2 gene on peripheral CD4+ T cells.
  • These findings contribute to better understanding of biological effects of asbestos in respect to the duration and intensity of exposure.
  • [MeSH-major] Asbestos / immunology. Asbestosis / immunology. Mesothelioma / immunology. Pleural Neoplasms / immunology

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20853778.001).
  • [ISSN] 0004-1254
  • [Journal-full-title] Arhiv za higijenu rada i toksikologiju
  • [ISO-abbreviation] Arh Hig Rada Toksikol
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


28. Creaney J, Robinson BW: Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein. Hematol Oncol Clin North Am; 2005 Dec;19(6):1025-40, v
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein.
  • Malignant mesothelioma (MM) is strongly associated with asbestos exposure.
  • Measurement of soluble mesothelin-related protein (SMRP) levels in the serum may prove valuable as an adjunct to current tests for the diagnosis of MM and for monitoring MM patients for the early detection of disease recurrence.
  • Although individuals with occupational and nonoccupational asbestos exposure are justifiably concerned about their risk of developing MM, consideration must be given to the complex issues surrounding screening for this disease, and a more substantial evaluation of the SMRP marker must be undertaken before deciding to promote a screening program.
  • [MeSH-major] Asbestos / adverse effects. Mesothelioma / diagnosis. Mesothelioma / etiology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16325121.001).
  • [ISSN] 0889-8588
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 1332-21-4 / Asbestos
  • [Number-of-references] 62
  •  go-up   go-down


29. Lotti M, Bergamo L, Murer B: Occupational toxicology of asbestos-related malignancies. Clin Toxicol (Phila); 2010 Jul;48(6):485-96
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occupational toxicology of asbestos-related malignancies.
  • INTRODUCTION: Asbestos is banned in most Western countries but related malignancies are still of clinical concern because of their long latencies.
  • This review identifies and addresses some controversial occupational and clinical aspects of asbestos-related malignancies.
  • In addition, fibers and asbestos bodies are counted in lung tissue, broncho-alveolar lavage, and sputum, but different techniques and interlaboratory variability hamper the interpretation of reported measurements.
  • Several biomarkers have also been considered to screen individuals at risk for lung cancer and mesothelioma but reliable signatures are still missing.
  • However, the unresolved question is whether the presence of fibrosis is a requirement for the attribution of lung cancer to asbestos.
  • The etiology of lung cancer is difficult to define in cases of low-level asbestos exposure and concurrent smoking habits.
  • MESOTHELIOMA: The diagnosis of malignant mesothelioma may also be difficult, because of procedures in sampling, fixation, and processing, and uses of immunohistochemical probes.
  • Quantitative analysis of asbestos body burden is better performed in digested lung tissues by counting asbestos bodies by light microscopy and/or uncoated fibers by transmission electron microscopy.
  • The benefits of screenings for asbestos-related malignancies are equivocal.
  • The attribution of lung cancer to asbestos exposure is difficult in a clinical setting because of the need to assess asbestos body burden and the fact that virtually all these patients are also tobacco smokers or former smokers.
  • Given the premise that asbestosis is necessary to causally link lung cancer to asbestos, it follows that the assessment of both lung fibrosis and asbestos body burden is necessary.
  • [MeSH-major] Asbestos / toxicity. Lung Neoplasms / chemically induced. Mesothelioma / chemically induced. Occupational Exposure / adverse effects

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20849338.001).
  • [ISSN] 1556-9519
  • [Journal-full-title] Clinical toxicology (Philadelphia, Pa.)
  • [ISO-abbreviation] Clin Toxicol (Phila)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 1332-21-4 / Asbestos
  •  go-up   go-down


30. Hieckel HG, Hering KG: [Asbestos-related diseases of the thorax]. Radiologe; 2010 Jul;50(7):623-33; quiz 634
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Asbestos-related diseases of the thorax].
  • Asbestos fibers can lead to pulmonary fibrosis, thickening of the pleura and malignancies.
  • These pathologic changes are possible rather than determinate and depend on the type of asbestos fiber, length of exposure to fibers and individual factors.
  • In Germany asbestos fibers were widely used until 1993.
  • Worldwide, there is currently no general ban on the use of asbestos.
  • The leading cause of asbestos-related diseases is occupational exposure.
  • Occupationally-derived asbestos-related diseases of the thorax are asbestosis, asbestos-related benign pleurisy and malignant pleural mesothelioma.
  • Bronchial carcinoma can also be caused by asbestos exposure.
  • [MeSH-major] Asbestosis / diagnosis. Carcinoma, Bronchogenic / diagnosis. Lung Neoplasms / diagnosis. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Pleurisy / diagnosis

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pneumologie. 2003 Oct;57(10 ):576-84 [14569528.001]
  • [Cites] Eur Respir J. 1998 May;11(5):1021-7 [9648950.001]
  • [Cites] AJR Am J Roentgenol. 2003 Jul;181(1):163-9 [12818850.001]
  • [Cites] Pneumologie. 2009 Nov;63(11):664-8 [19862671.001]
  • [Cites] J Thorac Oncol. 2009 May;4(5):620-8 [19357540.001]
  • [Cites] Pneumologie. 2009 Dec;63(12 ):726-32 [19937572.001]
  • [Cites] Radiologe. 2004 May;44(5):500-11 [15094995.001]
  • [Cites] Radiology. 2003 Dec;229(3):731-6 [14576443.001]
  • (PMID = 20521020.001).
  • [ISSN] 1432-2102
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  •  go-up   go-down


31. Scattone A, Pennella A, Gentile M, Musti M, Nazzaro P, Buonadonna AL, Marzullo A, Cavone D, Pollice L, Serio G: Comparative genomic hybridisation in malignant deciduoid mesothelioma. J Clin Pathol; 2006 Jul;59(7):764-9
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative genomic hybridisation in malignant deciduoid mesothelioma.
  • BACKGROUND: Malignant deciduoid mesothelioma is a rare variant of epithelioid mesothelioma.
  • This tumour generally has poor prognosis, and can be asbestos related.
  • AIM: To identify peculiar genetic changes responsible for critical phases in pathogenesis of malignant deciduoid mesothelioma and their prognostic relevance.
  • METHODS: Comparative genomic hybridisation was carried out in six cases of malignant pleural deciduoid mesothelioma, four sporadic and two familial.
  • All cases were found to be asbestos related.
  • The clinical outcome for this mesothelioma subtype is predicted by the number of losses.
  • [MeSH-major] Chromosome Aberrations. Mesothelioma / genetics. Pleural Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Asbestos / adverse effects. Female. Humans. Image Processing, Computer-Assisted. Immunoenzyme Techniques. Male. Middle Aged. Nucleic Acid Hybridization / methods. Occupational Diseases / etiology. Occupational Diseases / genetics. Occupational Diseases / pathology. Prognosis. Retrospective Studies

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Aug;24(8):1179 [10935666.001]
  • [Cites] Virchows Arch. 1999 Mar;434(3):263-6 [10190309.001]
  • [Cites] Thorax. 2000 Sep;55(9):731-5 [10950889.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1440-3 [11023112.001]
  • [Cites] Clin Ter. 2000 Nov-Dec;151(6):433-8 [11211478.001]
  • [Cites] J Mol Diagn. 2000 Nov;2(4):209-16 [11232111.001]
  • [Cites] Cytopathology. 2001 Feb;12(1):57-61 [11256939.001]
  • [Cites] Am J Surg Pathol. 2001 Apr;25(4):547-8 [11257636.001]
  • [Cites] Cancer Genet Cytogenet. 2001 May;127(1):80-2 [11408072.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Aug;31(4):333-44 [11433524.001]
  • [Cites] Ann Diagn Pathol. 2001 Jun;5(3):168-71 [11436171.001]
  • [Cites] Histopathology. 2001 Jul;39(1):104-6 [11454052.001]
  • [Cites] Oncogene. 2001 Sep 27;20(43):6245-9 [11593434.001]
  • [Cites] Diagn Cytopathol. 2002 Feb;26(2):117-22 [11813331.001]
  • [Cites] Indian J Pathol Microbiol. 2001 Apr;44(2):159-62 [11883137.001]
  • [Cites] Histopathology. 2002 Apr;40(4):348-52 [11943019.001]
  • [Cites] J Pathol. 2002 Jul;197(3):363-71 [12115883.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Oct 1;138(1):73-6 [12419589.001]
  • [Cites] Cancer Biol Ther. 2002 Jul-Aug;1(4):348-53 [12432244.001]
  • [Cites] Ultrastruct Pathol. 2002 Nov-Dec;26(6):355-63 [12537760.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3B):2281-9 [12894504.001]
  • [Cites] Pathol Int. 2004 Jan;54(1):67-72 [14674999.001]
  • [Cites] Pathol Int. 2004 Aug;54(8):549-55 [15260845.001]
  • [Cites] Am J Clin Pathol. 1981 Jun;75(6):816-21 [6167159.001]
  • [Cites] Am J Surg Pathol. 1985 Jan;9(1):73-80 [3970301.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Mar;59(1):57-61 [1555192.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4349-55 [8364929.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2156-60 [8134364.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7):1801-6 [8137295.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):439-45 [7513500.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Aug;10(4):231-43 [7522536.001]
  • [Cites] Am J Pathol. 1994 Dec;145(6):1301-8 [7992835.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):342-7 [7529134.001]
  • [Cites] J Cell Physiol. 1999 Aug;180(2):150-7 [10395284.001]
  • [Cites] Chest. 1999 Aug;116(2):504-20 [10453882.001]
  • [Cites] Am J Pathol. 1999 Sep;155(3):683-94 [10487825.001]
  • [Cites] Histopathology. 2004 Dec;45(6):643-5 [15569059.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Nov;11(3):153-62 [7530484.001]
  • [Cites] Chest. 1995 Oct;108(4):1122-8 [7555126.001]
  • [Cites] Am J Hum Genet. 1995 Nov;57(5):1211-20 [7485173.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Jul 1;89(1):7-13 [8689616.001]
  • [Cites] Br J Cancer. 1997;75(4):523-7 [9052404.001]
  • [Cites] Cancer Res. 1997 Sep 15;57(18):4057-62 [9307293.001]
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):285-94 [10680897.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):816-23 [10843283.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Jul;28(3):337-41 [10862040.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Aug;28(4):395-403 [10862048.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Jan 1;100(1):25-30 [9406576.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):145-52 [9440736.001]
  • [Cites] Br J Cancer. 1998;77(2):260-9 [9460997.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):450-4 [9927061.001]
  • [Cites] Respiration. 2000;67(4):456-8 [10940805.001]
  • (PMID = 16569690.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  • [Other-IDs] NLM/ PMC1860431
  •  go-up   go-down


32. Matsuyama A, Hisaoka M, Iwasaki M, Iwashita M, Hisanaga S, Hashimoto H: TLE1 expression in malignant mesothelioma. Virchows Arch; 2010 Nov;457(5):577-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TLE1 expression in malignant mesothelioma.
  • Malignant mesothelioma, an aggressive and often lethal tumor commonly associated with asbestos exposure, has been morphologically classified into epithelial, biphasic, and sarcomatoid subtypes.
  • Histological distinction between biphasic or sarcomatoid mesothelioma and synovial sarcoma may be problematic in certain circumstances of intrathoracic location because of their similar clinicopathologic features, including not only their morphology but also occasional positive immunoreaction of mesothelioma markers.
  • TLE1, which plays an important role in Wnt pathway, has been shown to be a specific marker for synovial sarcoma and diagnostically is useful; however, TLE1 expression in malignant mesotheliomas has not been fully evaluated.
  • We immunohistochemically examined the expression of TLE1, factors related to the Wnt pathway including β-catenin and cyclin D1, and mesothelioma markers including calretinin, HBME-1, cytokeratin 5/6, and thrombomodulin in 29 malignant mesotheliomas.
  • TLE1 was variably expressed in 28 malignant mesotheliomas regardless of histomorphological subtype with >25% of positive cells in 20 cases (69.0%).
  • Our study showed no or limited value of the immunohistochemical TLE1 expression in distinguishing malignant mesothelioma and synovial sarcoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Mesothelioma / metabolism. Mesothelioma / pathology. Repressor Proteins / biosynthesis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 May;25(5):610-7 [11342772.001]
  • [Cites] Histopathology. 2003 Mar;42(3):270-9 [12605647.001]
  • [Cites] J Pathol. 2003 Nov;201(3):355-62 [14595746.001]
  • [Cites] Environ Health Prev Med. 2008 Mar;13(2):65-70 [19568883.001]
  • [Cites] Genes Dev. 2009 Dec 1;23(23):2778-91 [19952112.001]
  • [Cites] Cancer Treat Res. 2004;119:217-37 [15164880.001]
  • [Cites] Am J Surg Pathol. 2007 Feb;31(2):240-6 [17255769.001]
  • [Cites] Am J Surg Pathol. 2009 Dec;33(12):1743-51 [19809272.001]
  • [Cites] Arch Pathol Lab Med. 2006 Jun;130(6):792-8 [16740029.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7562-70 [16885355.001]
  • [Cites] Mol Endocrinol. 2007 Aug;21(8):1877-92 [17519353.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):68-74 [15375433.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2427-33 [15830375.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9226-35 [16230383.001]
  • [Cites] Am J Surg Pathol. 2009 Aug;33(8):1179-86 [19417583.001]
  • [Cites] Eur J Cancer. 2010 Apr;46(6):1170-6 [20189377.001]
  • [Cites] Hum Pathol. 2004 Jul;35(7):850-6 [15257548.001]
  • [Cites] Histopathology. 1998 Dec;33(6):508-13 [9870144.001]
  • [Cites] Virchows Arch. 2010 Feb;456(2):141-51 [19412622.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1807-12 [9846971.001]
  • [Cites] Pathol Res Pract. 1996 Feb;192(2):137-47 [8692714.001]
  • [Cites] Nat Struct Mol Biol. 2005 Apr;12(4):364-71 [15768032.001]
  • [Cites] Oncogene. 2006 Jun 22;25(26):3661-9 [16462762.001]
  • [Cites] Mod Pathol. 2009 Jul;22(7):872-8 [19363472.001]
  • (PMID = 20857142.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Repressor Proteins; 0 / TLE1 protein, human
  •  go-up   go-down


33. Spiess PE, Tuziak T, Kassouf W, Grossman HB, Czerniak B: Malignant mesothelioma of the tunica vaginalis. Urology; 2005 Aug;66(2):397-401
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma of the tunica vaginalis.
  • OBJECTIVES: To review our experience with the management of malignant mesothelioma of the tunica vaginalis with emphasis on disease-related outcomes.
  • METHODS: A retrospective chart review of patients seen during the past 25 years at our cancer center identified 5 cases of malignant mesothelioma of the tunica vaginalis.
  • Asbestos exposure was identified in 4 patients.
  • CONCLUSIONS: Malignant mesothelioma of the tunica vaginalis constitutes a rare but often fatal malignancy of the male genitalia.
  • This diagnosis should be suspected in patients exposed to asbestos and presenting with clinical symptoms of either hydrocele or inguinal hernia.
  • [MeSH-major] Mesothelioma / pathology. Mesothelioma / surgery. Testicular Neoplasms / pathology. Testicular Neoplasms / surgery


34. Candura SM, Canto A, Amatu A, Gerardini M, Stella G, Mensi M, Poggi G: Malignant mesothelioma of the tunica vaginalis testis in a petrochemical worker exposed to asbestos. Anticancer Res; 2008 Mar-Apr;28(2B):1365-8
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma of the tunica vaginalis testis in a petrochemical worker exposed to asbestos.
  • Malignant mesothelioma of the tunica vaginalis testis is a rare and aggressive asbestos-related malignancy that may pose difficult diagnostic problems.
  • After 16 years of asbestos exposure, a 38-year-old petrochemical worker came to our notice with acute right testicular pain and swelling, simulating torsion of the spermatic cord.
  • Immunohistochemical staining for the epithelial glycoprotein Ber-EP4 was negative, whereas results were positive for mesothelial markers, thus leading to the diagnosis of epithelial mesothelioma.
  • Tunical mesothelioma may simulate metastatic carcinoma at routine histopathological examination.
  • Immunohistochemistry and occupational anamnesis are helpful for the correct diagnosis, which, in turn, is important for prognosis and treatment, and in relation to legal issues when asbestos is involved in the causation of the disease.
  • [MeSH-major] Asbestos / poisoning. Chemical Industry. Mesothelioma / etiology. Occupational Diseases / etiology. Occupational Exposure / adverse effects. Testicular Neoplasms / etiology


35. Aceto N, Bertino P, Barbone D, Tassi G, Manzo L, Porta C, Mutti L, Gaudino G: Taurolidine and oxidative stress: a rationale for local treatment of mesothelioma. Eur Respir J; 2009 Dec;34(6):1399-407
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Taurolidine and oxidative stress: a rationale for local treatment of mesothelioma.
  • Malignant mesothelioma is an asbestos-related, aggressive tumour, resistant to most anticancer therapies.
  • Akt is a key mediator of mesothelioma cell survival and chemoresistance.
  • This study aimed to clarify the mechanism by which taurolidine (TN), a known synthetic compound with antimicrobial and antineoplastic properties, leads to mesothelioma cell death.
  • TN induces cell death of mesothelioma cells, but not of non-neoplastic human mesothelial cells.
  • After TN treatment of mesothelioma cells, Akt but not extracellular signal-regulated kinase (Erk) 1/2 activity is inhibited a in time- and dose-dependent manner.
  • TN induces mesothelioma cell death via oxidative stress, accompanied by inhibition of Akt signalling.
  • This provides a promising molecular rationale for TN as local treatment of malignant mesothelioma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Mesothelioma / drug therapy. Mesothelioma / pathology. Oxidative Stress. Taurine / analogs & derivatives. Thiadiazines / therapeutic use


36. Comar M, Rizzardi C, de Zotti R, Melato M, Bovenzi M, Butel JS, Campello C: SV40 multiple tissue infection and asbestos exposure in a hyperendemic area for malignant mesothelioma. Cancer Res; 2007 Sep 15;67(18):8456-9
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SV40 multiple tissue infection and asbestos exposure in a hyperendemic area for malignant mesothelioma.
  • To assess the presence of SV40 in malignant mesothelioma tissue, 19 formalin-fixed paraffin-embedded pleural cancer samples of patients from a hyperendemic area of northeastern Italy were analyzed retrospectively.
  • A total of 48 other tissues from the malignant mesothelioma subjects were investigated.
  • Exposure to asbestos was evaluated through a careful review of the occupational history of patients, supplemented by histology and isolation of asbestos bodies.
  • Three of 19 (15.8%) malignant mesothelioma tissues harbored SV40 genomic signals.
  • Two patients with SV40-positive malignant mesothelioma had viral sequences in another tissue.
  • SV40 viral loads were higher in malignant mesothelioma than in normal cells (P = 0.045).
  • This survey shows that SV40 sustains infections in multiple tissues in malignant mesothelioma patients from a geographic area affected with asbestos-related mesothelioma.
  • [MeSH-major] Asbestos / adverse effects. Cocarcinogenesis. Mesothelioma / etiology. Pleural Neoplasms / etiology. Polyomavirus Infections / complications. Simian virus 40 / genetics. Tumor Virus Infections / complications

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875683.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA104818
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 1332-21-4 / Asbestos
  •  go-up   go-down


37. Dave SK, Beckett WS: Occupational asbestos exposure and predictable asbestos-related diseases in India. Am J Ind Med; 2005 Aug;48(2):137-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occupational asbestos exposure and predictable asbestos-related diseases in India.
  • BACKGROUND: India imports nearly 100,000 metric tons of asbestos per year, and small-scale asbestos (chrysotile and tremolite) mining and milling contributes nearly 5%-10% of the total national usage.
  • METHODS: Surveys of asbestos-exposed workers have identified significant occupational exposures, early pleural and parenchymal changes on chest radiograph, and decrements in lung function.
  • RESULTS AND CONCLUSIONS: Based on knowledge of past and current exposures to asbestos in industry, we can predict a future occurrence of clinical asbestos-related diseases-pleural changes, pulmonary fibrosis, bronchogenic carcinoma, and diffuse malignant mesothelioma.
  • These cases of asbestos related disease are expected to occur in asbestos exposed workers from mining, milling, and manufacturing as well as in those with secondary exposures to asbestos-containing materials, including construction and maintenance workers, users of asbestos-containing consumer products, and the occupants of asbestos-containing buildings.
  • [MeSH-major] Asbestos, Serpentine / toxicity. Asbestosis / epidemiology. Extraction and Processing Industry. Occupational Diseases / epidemiology. Occupational Exposure / adverse effects
  • [MeSH-minor] Forecasting. Humans. India / epidemiology. Mesothelioma / epidemiology. Mesothelioma / etiology

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16032742.001).
  • [ISSN] 0271-3586
  • [Journal-full-title] American journal of industrial medicine
  • [ISO-abbreviation] Am. J. Ind. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Asbestos, Serpentine
  •  go-up   go-down


38. Phillips JI, Murray J: Malignant mesothelioma in a patient with anthophyllite asbestos fibres in the lungs. Ann Occup Hyg; 2010 Jun;54(4):412-6
Hazardous Substances Data Bank. TALC .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma in a patient with anthophyllite asbestos fibres in the lungs.
  • The amphibole asbestos, anthophyllite, is associated with asbestos-related disease in humans, along with mesothelioma in animal models.
  • In humans, however, there are only three cases of histologically proven malignant mesothelioma of the pleura associated with anthophyllite that have been documented in the English-language literature.
  • Using scanning electron microscopy, his lung fibre burden was calculated to be 358,000 fibres and 31,000 asbestos bodies per gram of dry weight of lung tissue.
  • No other types of asbestos were detected in the lung.
  • He worked in the plastic manufacturing industry and was exposed to talc and asbestos blankets that were used to insulate machinery.
  • [MeSH-major] Asbestos, Amphibole / toxicity. Mesothelioma / diagnosis. Occupational Diseases / diagnosis. Pleural Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20427324.001).
  • [ISSN] 1475-3162
  • [Journal-full-title] The Annals of occupational hygiene
  • [ISO-abbreviation] Ann Occup Hyg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Asbestos, Amphibole; 0 / Mineral Fibers; 0 / Plastics; 14807-96-6 / Talc; 61029-21-8 / anthophyllite
  •  go-up   go-down


39. Tse LA, Yu IT, Goggins W, Clements M, Wang XR, Au JS, Yu KS: Are current or future mesothelioma epidemics in Hong Kong the tragic legacy of uncontrolled use of asbestos in the past? Environ Health Perspect; 2010 Mar;118(3):382-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Are current or future mesothelioma epidemics in Hong Kong the tragic legacy of uncontrolled use of asbestos in the past?
  • Inhaled asbestos fibers may contribute to three-fourths of malignant mesotheliomas diagnosed in men and almost 40% of cases diagnosed in women.
  • Bans on the manufacture and sale of amphibole asbestos fibers are expected to reduce the incidence of mesothelioma, but the long latency period from initial exposure to clinical disease means that people exposed before bans were enacted will continue to develop asbestos-related mesotheliomas as they age.
  • Tse et al. (p. 382) used historical data on asbestos consumption and mesothelioma diagnoses to predict future mesothelioma trends in Hong Kong.
  • Asbestos use peaked during a construction boom in the early 1960s and subsequently declined by > 90% following a ban on the sale and import of crocidolite and amosite asbestos in 1996, whereas mesothelioma diagnoses in men increased from a single case in 1972–1976 to 63 cases in 2002–2006 (corresponding to crude incidence rates of 0.09 and 3.86 cases/million men, respectively).
  • However, they caution that ongoing use of chrysotile asbestos and the release of asbestos fibers from older buildings during demolition or renovation may slow the projected decline. [corrected]
  • [MeSH-major] Asbestos / adverse effects. Mesothelioma / chemically induced. Mesothelioma / epidemiology. Occupational Exposure / adverse effects

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Occup Environ Med. 1994 Dec;51(12):793-8 [7849861.001]
  • [Cites] Agric Hist. 2009 Winter;83(1):51-78 [19618528.001]
  • [Cites] Am J Ind Med. 2000 Feb;37(2):159-68 [10615096.001]
  • [Cites] Ann Occup Hyg. 2000 Dec;44(8):565-601 [11108782.001]
  • [Cites] Int Arch Occup Environ Health. 2001 Aug;74(6):383-95 [11563601.001]
  • [Cites] Tumori. 2002 Jan-Feb;88(1):1-9 [12004841.001]
  • [Cites] J Occup Environ Med. 2003 Apr;45(4):456-61 [12708150.001]
  • [Cites] Int J Cancer. 2003 Oct 20;107(1):94-8 [12925962.001]
  • [Cites] Int J Occup Environ Health. 2003 Jul-Sep;9(3):206-17 [12967156.001]
  • [Cites] Am J Epidemiol. 2004 Jan 15;159(2):107-12 [14718210.001]
  • [Cites] Lancet. 1982 Nov 13;2(8307):1101-3 [6127563.001]
  • [Cites] Trop Geogr Med. 1983 Sep;35(3):225-9 [6316591.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):1912-20 [1848472.001]
  • [Cites] Lung Cancer. 2009 Oct;66(1):22-7 [19185950.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):666-72 [10027347.001]
  • [Cites] Respir Med. 2006 Jan;100(1):75-82 [15941656.001]
  • [Cites] Jpn J Clin Oncol. 2006 Apr;36(4):254-7 [16684861.001]
  • [Cites] Occup Environ Med. 2006 Jun;63(6):390-5 [16469823.001]
  • [Cites] Lancet. 2007 Mar 10;369(9564):844-9 [17350453.001]
  • [Cites] Scand J Work Environ Health. 2007 Aug;33(4):286-92 [17717621.001]
  • [Cites] Int J Occup Environ Health. 2008 Jul-Sep;14(3):170-5 [18686716.001]
  • [Cites] Crit Rev Toxicol. 2008;38 Suppl 1:49-73 [18686078.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Sep 15;178(6):624-9 [18556631.001]
  • [Cites] Environ Health Perspect. 2008 Dec;116(12):1675-80 [19079719.001]
  • [Cites] Am J Ind Med. 2009 Apr;52(4):282-7 [19143009.001]
  • [CommentIn] Environ Health Perspect. 2010 Jul;118(7):A282 [20601327.001]
  • [ErratumIn] Environ Health Perspect. 2010 Jun;118(6):A240
  • (PMID = 20064790.001).
  • [ISSN] 1552-9924
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  • [Other-IDs] NLM/ PMC2854767
  •  go-up   go-down


40. Riganti C, Doublier S, Aldieri E, Orecchia S, Betta PG, Gazzano E, Ghigo D, Bosia A: Asbestos induces doxorubicin resistance in MM98 mesothelioma cells via HIF-1alpha. Eur Respir J; 2008 Aug;32(2):443-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asbestos induces doxorubicin resistance in MM98 mesothelioma cells via HIF-1alpha.
  • Human malignant mesothelioma (HMM), which is strongly related to asbestos exposure, exhibits high resistance to many anticancer drugs.
  • Asbestos fibre deposition in the lung may cause hypoxia and iron chelation at the fibre surface.
  • The present study aimed to assess whether asbestos may play a role in the induction of doxorubicin resistance in HMM cells through the activation of HIF-1alpha and an increased expression of Pgp.
  • After 24-h incubation with crocidolite asbestos or with the iron chelator dexrazoxane, or under hypoxia, HMM cells were tested for HIF-1alpha activation, Pgp expression, accumulation of doxorubicin and sensitivity to its toxic effect.
  • Crocidolite, dexrazoxane and hypoxia induce doxorubicin resistance in human malignant mesothelioma cells by increasing hypoxia-inducible factor-1alpha activity, through an iron-sensitive mechanism.
  • [MeSH-major] Asbestos / toxicity. Drug Resistance, Neoplasm. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Lung Neoplasms / drug therapy. Mesothelioma / drug therapy
  • [MeSH-minor] Anoxia. Antineoplastic Agents / pharmacology. Asbestos, Crocidolite / pharmacology. Cell Line, Tumor. Doxorubicin / pharmacology. Humans. Iron / metabolism. Lung / pathology. P-Glycoprotein / metabolism. Razoxane / pharmacology

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18385176.001).
  • [ISSN] 1399-3003
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / P-Glycoprotein; 12001-28-4 / Asbestos, Crocidolite; 1332-21-4 / Asbestos; 5AR83PR647 / Razoxane; 80168379AG / Doxorubicin; E1UOL152H7 / Iron
  •  go-up   go-down


41. Gaafar RM, Eldin NH: Epidemic of mesothelioma in Egypt. Lung Cancer; 2005 Jul;49 Suppl 1:S17-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemic of mesothelioma in Egypt.
  • Asbestos has been recognized in Egypt since a long time as ancient Egyptians were using it in mummification.
  • Mesothelioma in Egypt is mainly attributed to environmental origin with a high incidence of women and young adults affected.
  • The incidence of mesothelioma is rising in Egypt.
  • Epidemiological data for 635 malignant mesothelioma (MM) patients over 4 years in the third Millennium were collected from the National Cancer Institute (NCI), Cairo University and Abbassia Chest hospital.
  • A clinicopathological study was done for 100 malignant pleural mesothelioma (MPM) patients and showed that asbestos exposure and SV40 positivity were evident in 67% and 60% of cases, respectively.
  • Evaluation of p53 and pRb immunohistochemically showed that pRb alteration was related to poor survival.
  • Asbestos in Cairo is a silent killer and measures toward eliminating it entirely or at least strictly controlling human contact with this dangerous carcinogen have to be taken in order to combat the coming epidemic of mesothelioma in Egypt.
  • [MeSH-major] Asbestos / adverse effects. Disease Outbreaks. Mesothelioma / epidemiology. Pleural Neoplasms / epidemiology


42. Rodríguez Portal JA, Rodríguez Becerra E, Rodríguez Rodríguez D, Alfageme Michavila I, Quero Martínez A, Diego Roza C, León Jiménez A, Isidro Montes I, Cebollero Rivas P: Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev; 2009 Feb;18(2):646-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
  • BACKGROUND: Malignant pleural mesothelioma (MPM) results from malignant transformation of mesothelial cells.
  • Past asbestos exposure represents a major risk factor for MPM and other benign pleural disease.
  • Soluble mesothelin-related peptides (SMRP) have been regarded as a promising serum biomarker for MPM.
  • The aim of this study was to investigate serum levels of SMRP in malignant and nonmalignant asbestos-related pleural disease.
  • PATIENTS: Four groups of patients were investigated: group 1 composed of 48 healthy subjects, group 2 composed of 177 patients with previous asbestos exposure and no pleural disease, group 3 composed of 36 patients with MPM, and group 4 composed of 101 patients with previous asbestos exposure and benign pleural disease.
  • Subjects exposed to asbestos had higher SMRP concentrations than normal control subjects regardless of the presence of pleural disease.
  • CONCLUSIONS: These data attest to good diagnostic sensitivity and specificity of SMRP for the diagnosis of malignant mesothelioma.
  • We have also shown that serum SMRP levels might serve as a marker of asbestos exposure.
  • [MeSH-major] Asbestosis / blood. Biomarkers, Tumor / blood. Membrane Glycoproteins / blood. Mesothelioma / blood. Pleural Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190155.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


43. Baas P, van 't Hullenaar N, Wagenaar J, Kaajan JP, Koolen M, Schrijver M, Schlösser N, Burgers JA: Occupational asbestos exposure: how to deal with suspected mesothelioma cases--the Dutch approach. Ann Oncol; 2006 May;17(5):848-52
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occupational asbestos exposure: how to deal with suspected mesothelioma cases--the Dutch approach.
  • INTRODUCTION: Patients with asbestos-related diseases, such as malignant mesothelioma (MM), are not uniformly treated in Europe when they apply for compensation.
  • In The Netherlands, the Institute of Asbestos Victims (IAV) acts on behalf of patients with a malignant mesothelioma.
  • In these cases a specialist opinion of the Mesothelioma Group of the Dutch Thoracic Society (DTS) is required.
  • MATERIALS AND METHODS: Dutch patients with a possible malignant mesothelioma and occupational exposure to asbestos presented their cases to the IAV.
  • In 10% of the cases, pathological confirmation of a malignant mesothelioma could not be obtained.
  • These cases were presented to the Mesothelioma Group to obtain a clinical diagnosis based on clinical reports, occupational history, X-ray examination and other factors.
  • In 161 cases no definitive diagnosis could be made on pathology and were presented to the Mesothelioma Group.
  • Of these cases, 117 (73%) were considered to be compatible with the clinical diagnosis malignant pleural mesothelioma.
  • CONCLUSIONS: Compared with other European countries, this approach, as determined by the IAV and Mesothelioma Group of the DTS, is an effective and rapid way to investigate claims of patients with a possible occupationally related malignant mesothelioma.

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16500906.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Air Pollutants; 1332-21-4 / Asbestos
  •  go-up   go-down


44. Creaney J, Segal A, Sterrett G, Platten MA, Baker E, Murch AR, Nowak AK, Robinson BW, Millward MJ: Overexpression and altered glycosylation of MUC1 in malignant mesothelioma. Br J Cancer; 2008 May 6;98(9):1562-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression and altered glycosylation of MUC1 in malignant mesothelioma.
  • However, little is known of the characteristics of MUC1/EMA in mesothelioma.
  • Herein, we studied the cell surface and soluble expression of the MUC1/EMA glycoprotein, and determined the mRNA and genomic expression profiles in mesothelioma.
  • MUC1 mRNA expression was significantly higher in mesothelioma samples than in benign mesothelial cells.
  • Seven of 9 mesothelioma samples expressed MUC1-secreted mRNA isoform in addition to the archetypal MUC1/transmembrane form.
  • CA15.3 (soluble MUC1) levels were significantly higher in the serum of mesothelioma patients than in healthy controls but were not significantly different to levels in patients with benign asbestos-related disease.
  • CA15-3 in effusions could differentiate malignant from benign effusions but were not specific for mesothelioma.
  • Thus, as in other cancers, alterations in MUC1 biology occur in mesothelioma and these results suggest that specific MUC1 characteristics may be useful for mesothelioma diagnosis and should also be investigated as a potential therapeutic target.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Mesothelioma / diagnosis. Mesothelioma / metabolism. Mucin-1 / metabolism. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / metabolism

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Nov;81(6):1059-65 [10576665.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5129-35 [16951230.001]
  • [Cites] Cytopathology. 2000 Jun;11(3):139-51 [10877273.001]
  • [Cites] Blood. 2000 Nov 1;96(9):3102-8 [11049990.001]
  • [Cites] Lung Cancer. 2001 Jan;31(1):9-16 [11162861.001]
  • [Cites] Curr Opin Mol Ther. 2001 Feb;3(1):102-5 [11249725.001]
  • [Cites] Int J Cancer. 2002 Jul 10;100(2):166-71 [12115565.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):209-21 [12463741.001]
  • [Cites] Clin Breast Cancer. 2003 Feb;3 Suppl 4:S134-8 [12620150.001]
  • [Cites] Lung Cancer. 2003 Jun;40(3):289-94 [12781427.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1031-51 [12883236.001]
  • [Cites] Histopathology. 2004 Feb;44(2):147-55 [14764058.001]
  • [Cites] Crit Rev Clin Lab Sci. 2004;41(2):189-231 [15270554.001]
  • [Cites] Arch Pathol Lab Med. 2004 Oct;128(10):1131-5 [15387710.001]
  • [Cites] Ann Intern Med. 1972 Oct;77(4):507-13 [4642731.001]
  • [Cites] Br J Cancer. 1985 Sep;52(3):347-54 [3899155.001]
  • [Cites] Cancer Res. 1993 Feb 15;53(4):755-61 [7679050.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23 Suppl):5847s-5851s [7493358.001]
  • [Cites] Tumour Biol. 1998;19 Suppl 1:88-99 [9422093.001]
  • [Cites] Tumour Biol. 1998;19 Suppl 1:111-7 [9422095.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):583-90 [9452278.001]
  • [Cites] Diagn Cytopathol. 2005 Mar;32(3):156-9 [15690334.001]
  • [Cites] Lancet. 2005 Jul 30-Aug 5;366(9483):397-408 [16054941.001]
  • [Cites] Oncologist. 2005 Aug;10(7):501-7 [16079317.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1295-304 [15976813.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):405-11 [16052519.001]
  • [Cites] Cancer Immunol Immunother. 2006 Jan;55(1):63-7 [15864588.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):869-77 [16467101.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5910-8 [16740731.001]
  • [Cites] J Urol. 2006 Jul;176(1):91-5 [16753376.001]
  • [Cites] Tumour Biol. 2000 Jul-Aug;21(4):197-210 [10867613.001]
  • (PMID = 18454162.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2391110
  •  go-up   go-down


45. Riva MA, Carnevale F, Sironi VA, De Vito G, Cesana G: Mesothelioma and asbestos, fifty years of evidence: Chris Wagner and the contribution of the Italian occupational medicine community. Med Lav; 2010 Nov-Dec;101(6):409-15
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelioma and asbestos, fifty years of evidence: Chris Wagner and the contribution of the Italian occupational medicine community.
  • BACKGROUND: One of the first studies that "convincingly" described the relationship between pleural mesothelioma and asbestos was made by Wagner, Sleggs and Marchard in 1960.
  • This article, published fifty years ago, contains much of what we still know to-day about malignant mesothelioma.
  • OBJECTIVES: The aims of this article were to analyze the historical and scientific developments that led to the publication of Wagner's paper, to critically examine its contents and to consider the contribution to the initernational debate on the carcinogenesis of asbestos fibres made by occupational medicine in Italy in that period.
  • METHODS: A thorough analysis ofscientific and historical literature on the relationship between asbestos exposure and tumours was conducted, with special regard to the articles by Italian authors in the 1960's.
  • RESULTS: The decisive role of Wagner's paper in understanding the aetiopathogenetic mechanisms of asbestos-related tumours is inconfutable.
  • Enrico Vigliani, then director of the "Clinica del Lavoro" in Milan, made important contributions to this debate, also through the collection of data regarding mortality among Italian asbestos workers.
  • [MeSH-major] Asbestos / adverse effects. Mesothelioma / history. Occupational Diseases / history. Occupational Medicine. Pleural Neoplasms / history

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21141345.001).
  • [ISSN] 0025-7818
  • [Journal-full-title] La Medicina del lavoro
  • [ISO-abbreviation] Med Lav
  • [Language] eng
  • [Publication-type] Biography; Historical Article; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Mineral Fibers; 1332-21-4 / Asbestos
  • [Personal-name-as-subject] Wagner JC
  •  go-up   go-down


46. Governa M, Amati M, Bellis D, Bichisecchi E, Santarelli L: Diagnosis of asbestos-related pleuropolmonary diseases. Med Lav; 2006 May-Jun;97(3):463-74
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of asbestos-related pleuropolmonary diseases.
  • A revision of criteria for diagnosis of asbestos-related pathological conditions was performed studying specially asbestosis, pleural plaques and malignant mesothelioma, also taking into account the problems connected with histopathology.
  • As regards the histological diagnosis of asbestosis, it requires the presence of diffuse interstitialfibrosis in a well inflated tissue remote from the site of a tumour or other large lesion, plus the presence of two or more asbestos bodies in a 1 cm2 section.
  • As regards the pleural plaques and asbestos bodies we remark that they are merely exposition markers.
  • We also discussed the problems the pathologist may encounter in diagnosing mesothelioma; in this field the prospects are encouraging as microarray analysis are beginning to identify new molecular markers for mesothelioma.
  • [MeSH-major] Asbestos / adverse effects. Asbestosis / diagnosis. Lung Neoplasms / diagnosis. Lung Neoplasms / etiology. Mesothelioma / diagnosis. Mesothelioma / etiology. Pleural Diseases / diagnosis. Pleural Diseases / etiology

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Pleural Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17009682.001).
  • [ISSN] 0025-7818
  • [Journal-full-title] La Medicina del lavoro
  • [ISO-abbreviation] Med Lav
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  • [Number-of-references] 77
  •  go-up   go-down


47. Toyooka S, Kishimoto T, Date H: Advances in the molecular biology of malignant mesothelioma. Acta Med Okayama; 2008 Feb;62(1):1-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advances in the molecular biology of malignant mesothelioma.
  • Malignant mesothelioma (MM) is a highly aggressive tumor with a dismal prognosis.
  • The incidence of MM is increasing as a result of widespread exposure to asbestos.
  • As in other malignant tumors, genes that are related to immortalization, proliferation, metastasis, angiogenesis, and anti-apoptosis are also overexpressed in MM, contributing to its malignant phenotype.
  • Although the causative role of asbestos is well-known in MM, much less information is available for MM than for other malignant tumors regarding the molecular alterations that occur in the disease.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Mesothelioma / genetics. Neoplasms, Glandular and Epithelial / genetics. Pleural Neoplasms / genetics

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18323865.001).
  • [ISSN] 0386-300X
  • [Journal-full-title] Acta medica Okayama
  • [ISO-abbreviation] Acta Med. Okayama
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Number-of-references] 67
  •  go-up   go-down


48. Scarselli A, Binazzi A, Altavista P, Mastrantonio M, Uccelli R, Marinaccio A: [Malignant pleural cancers mortality and compensated cases for asbestos related diseases in Lazio municipalities (1980-2001)]. Med Lav; 2007 Jan-Feb;98(1):30-8
MedlinePlus Health Information. consumer health - Asbestos.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant pleural cancers mortality and compensated cases for asbestos related diseases in Lazio municipalities (1980-2001)].
  • BACKGROUND: Occupational exposure to asbestos has been widely reported in the Region, but a high risk for non-occupational and environmental contaminations have also been documented.
  • CONCLUSIONS: Epidemiological surveillance of incident cases of malignant mesothelioma in the Lazio Region and the investigation of modalities of asbestos exposure are urgently needed for prevention of occupational diseases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17240643.001).
  • [ISSN] 0025-7818
  • [Journal-full-title] La Medicina del lavoro
  • [ISO-abbreviation] Med Lav
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


49. Sarić M: [Expectations after ban on asbestos]. Arh Hig Rada Toksikol; 2009 Nov;60 Suppl:15-21
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expectations after ban on asbestos].
  • This article brings a brief review of asbestos exposure and asbestos-related diseases in Croatia in view of the asbestos ban.
  • The first cases of asbestosis were diagnosed in workers from an asbestos-cement factory in 1961.
  • As a rule, asbestos-related changes were diagnosed at an early stage thanks to regular checkups of the exposed workers.
  • Pleural plaques, considered to be the consequence of asbestos exposure, were also occasionally found in subjects who lived in areas with asbestos processing plants, but were not occupationally exposed.
  • Early epidemiological studies on respiratory and gastrointestinal tract tumours in areas with an asbestos processing plant (1994) and an asbestos-cement plant (1995, 1996) focused on the occurrence of malignant tumours in persons exposed to asbestos at work or in the environment.
  • More recently, the focus has shifted to the malignant pleural mesotelioma (MPM).
  • About two thirds of patients with the tumour were occupationally exposed to asbestos.
  • This uneven distribution of the tumour incidence is obviously related to shipbuilding and other industrial sources of asbestos exposure located in the coastal Croatia.
  • Sources of environmental exposure to asbestos also have to be taken into account.
  • The second part of this article ventures into the issues ahead of us, after asbestos has been banned in the country.
  • The long latency period of cancers, and particularly of asbestos-related mesothelioma, implies that the incidence of this tumour will not drop over the next few decades.
  • Sadly, the diagnosis of mesothelioma is seldom timely, and treatment is usually unsuccessful.
  • [MeSH-major] Asbestos / adverse effects. Asbestosis / epidemiology. Environmental Exposure / legislation & jurisprudence. Occupational Exposure / legislation & jurisprudence
  • [MeSH-minor] Croatia / epidemiology. Female. Humans. Male. Mesothelioma / epidemiology. Mesothelioma / etiology. Mesothelioma / prevention & control

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20853774.001).
  • [ISSN] 0004-1254
  • [Journal-full-title] Arhiv za higijenu rada i toksikologiju
  • [ISO-abbreviation] Arh Hig Rada Toksikol
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


50. O'Lone EL, Park EK, Sandrini A, Fogarty GB, Yates DH: Early detection of malignant pleural mesothelioma through measurement of soluble mesothelin-related protein and positron emission tomography. Med J Aust; 2009 Feb 2;190(3):158-9
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early detection of malignant pleural mesothelioma through measurement of soluble mesothelin-related protein and positron emission tomography.
  • A 51-year-old man with no known history of asbestos exposure presented with hydropneumothorax.
  • Soluble mesothelin-related protein testing and combined positron emission tomography and computed tomography were used to diagnose malignant pleural mesothelioma.
  • [MeSH-major] Hydropneumothorax / diagnosis. Membrane Glycoproteins / metabolism. Mesothelioma / diagnosis. Positron-Emission Tomography
  • [MeSH-minor] Asbestos / toxicity. Early Detection of Cancer. GPI-Linked Proteins. Humans. Male. Middle Aged. Time Factors

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19203317.001).
  • [ISSN] 0025-729X
  • [Journal-full-title] The Medical journal of Australia
  • [ISO-abbreviation] Med. J. Aust.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 1332-21-4 / Asbestos
  •  go-up   go-down


51. Azim HA Jr, Gaafar R, Abdel Salam I, El-Guindy S, Elattar I, Ashmawy A, Khorshid O: Soluble mesothelin-related protein in malignant pleural mesothelioma. J Egypt Natl Canc Inst; 2008 Sep;20(3):224-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble mesothelin-related protein in malignant pleural mesothelioma.
  • BACKGROUND AND PURPOSE: Building-up evidence suggests that soluble mesothelinrelated protein (SMRP) carries a diagnostic and a prognostic value in malignant pleural mesothelioma (MPM).
  • The mean SMRP concentrations were also higher in males, elderly patients, asbestos-exposed patients, epithelioid subtypes and patients with high platelet and leucocytic counts.
  • KEY WORDS: Malignant pleural mesothelioma (MPM) - Soluble mesothelin related protein (SMRP)- Sensitivity - Specificity - Asbestos.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20424652.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


52. Mise K, Jurcev-Savicević A, Bradarić A, Perić I, Barisić I, Puntarić D, Mise J, Ilić N: Increasing of malignant pleural mesothelioma: burning issue in Split-Dalmatian County, Croatia. Coll Antropol; 2009 Dec;33(4):1245-50
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increasing of malignant pleural mesothelioma: burning issue in Split-Dalmatian County, Croatia.
  • Asbestos-related diseases are one of the burning public health issues worldwide.
  • The incidence and the epidemiological patterns of malignant pleural mesothelioma in Split-Dalmatian County, where a large part of Croatian industry related to asbestos processing and use have been situated were assessed in this study.
  • The history of asbestos-related issues and development of current legislation in Croatia was also discussed briefly.
  • Data on the incidence were collected retrospectively from the medical records of patients with malignant pleural mesothelioma treated at Department of Pulmonary Diseases University Hospital Split during the 2000-2007 period.
  • The majority of patients were occupationally exposed to asbestos (85.4%), 8.8% had environmental exposure, and 2.2% had domestic exposure.
  • More than half of the cases were exposed to asbestos 31-40 years.
  • The incidence of malignant pleural mesothelioma in Split-Dalmatian County has been obviously increasing due to the predominantly occupational exposure and it is reasonable to assume that it will remain high in the next two-three decades and to be a reason for concern and fear among the general population.
  • [MeSH-major] Asbestos / adverse effects. Mesothelioma / epidemiology. Occupational Exposure / prevention & control. Pleural Neoplasms / epidemiology


53. Creaney J, van Bruggen I, Hof M, Segal A, Musk AW, de Klerk N, Horick N, Skates SJ, Robinson BW: Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest; 2007 Oct;132(4):1239-46
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
  • BACKGROUND: Malignant mesothelioma is an aggressive, uniformly fatal tumor.
  • The purpose of this study was to study the mesothelin biomarker in a large patient cohort and to determine if another biomarker, CA125, improves on the sensitivity of mesothelin in the diagnosis of mesothelioma.
  • METHODS: Serum levels of mesothelin and CA125 were determined by commercially available assays in 117 samples obtained at diagnosis from patients with pleural malignant mesothelioma, 33 healthy, asbestos-exposed individuals, 53 patients with asbestos-related lung or pleural disease, and 30 patients presenting with benign pleural effusions.
  • RESULTS: CA125 had a cross-validated sensitivity of 27% for mesothelioma patients at a specificity of 95% relative to asbestos-exposed individuals, or 50% relative to individuals with benign pleural effusions.
  • Mesothelin had a cross-validated sensitivity of 52% for mesothelioma patients, at a sensitivity of 95% relative to individuals with benign lung or pleural disease.
  • CA125 and mesothelin levels were discordant in > 50% of mesothelioma patients.
  • Combining the data from the two biomarkers using a logistic regression model did not improve sensitivity for detecting mesothelioma above that of the mesothelin marker alone.
  • CONCLUSION: Combining mesothelin and CA125 data does not improve the sensitivity of mesothelioma diagnosis over mesothelin alone.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Membrane Glycoproteins / blood. Mesothelioma / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17646232.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


54. Kricka O, Matanić Lender D, Barković I, Flego V, Kupanovac Z, Bulat Kardum L: [Malignant pleural mesothelioma in patients hospitalised at the Clinical Hospital Centre Rijeka between 1989 and 2008]. Arh Hig Rada Toksikol; 2009 Nov;60 Suppl:41-3
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant pleural mesothelioma in patients hospitalised at the Clinical Hospital Centre Rijeka between 1989 and 2008].
  • Malignant pleural mesothelioma (MPM) is a relatively rare tumour, mainly associated with occupational exposure to asbestos.
  • Occupational exposure to asbestos was established in 72 patients who worked in shipbuilding.
  • We believe that this is not related to improved diagnostics, but to the long latency of the disease.
  • In the U.S.A. and Europe, MPM incidence is expected to peak by 2020, while in countries with poor control over asbestos use this may take longer.
  • [MeSH-major] Asbestos / adverse effects. Mesothelioma / epidemiology. Occupational Diseases / epidemiology. Pleural Neoplasms / epidemiology


55. O'Reilly KM, Mclaughlin AM, Beckett WS, Sime PJ: Asbestos-related lung disease. Am Fam Physician; 2007 Mar 1;75(5):683-8
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asbestos-related lung disease.
  • The inhalation of asbestos fibers may lead to a number of respiratory diseases, including lung cancer, asbestosis, pleural plaques, benign pleural effusion, and malignant mesothelioma.
  • Patients with a history of significant asbestos exposure may warrant diagnostic testing and follow-up assessment, although it is unclear whether this improves outcomes.
  • Asbestosis generally progresses slowly, whereas malignant mesothelioma has an extremely poor prognosis.
  • The treatment of patients with asbestos exposure and lung cancer is identical to that of any patient with lung cancer.
  • Because exposure to cigarette smoke increases the risk of developing lung cancer in patients with a history of asbestos exposure, smoking cessation is essential.
  • [MeSH-major] Asbestos / adverse effects. Carcinogens / toxicity. Lung Diseases / etiology. Occupational Diseases / etiology. Occupational Exposure / adverse effects
  • [MeSH-minor] Asbestosis / etiology. Humans. Lung Neoplasms / etiology. Mesothelioma / etiology. Pleural Diseases / etiology

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [SummaryForPatientsIn] Am Fam Physician. 2007 Mar 1;75(5):690 [17375515.001]
  • (PMID = 17375514.001).
  • [ISSN] 0002-838X
  • [Journal-full-title] American family physician
  • [ISO-abbreviation] Am Fam Physician
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES01247
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 1332-21-4 / Asbestos
  • [Number-of-references] 18
  •  go-up   go-down


56. Davidson B: Expression of cancer-associated molecules in malignant mesothelioma. Biomark Insights; 2007 May 30;2:173-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cancer-associated molecules in malignant mesothelioma.
  • Malignant mesothelioma (MM) is a malignant tumor derived from mesothelial cells, native cells of the body cavities.
  • Exposure to asbestos is the most strongly established etiologic factor, predominantly for the most common disease form, pleural mesothelioma.
  • The pathogenesis of MM involves the accumulation of extensive cytogenetic changes, as well as cancer-related phenotypic alterations that facilitate tumor cell survival, invasion and metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 2001 Apr;193(4):468-75 [11276005.001]
  • [Cites] Int J Cancer. 2001 Mar 1;91(5):638-43 [11267973.001]
  • [Cites] Ann Diagn Pathol. 2000 Jun;4(3):143-8 [10919383.001]
  • [Cites] Br J Cancer. 2000 Nov;83(9):1147-53 [11027427.001]
  • [Cites] J Cell Physiol. 2000 Oct;185(1):126-34 [10942526.001]
  • [Cites] Int J Cancer. 2000 Oct 1;88(1):37-43 [10962437.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):415-21 [10821486.001]
  • [Cites] Mol Cell Biol Res Commun. 2000 Jan;3(1):26-32 [10683314.001]
  • [Cites] Histopathology. 2000 Jun;36(6):522-8 [10849094.001]
  • [Cites] Virchows Arch. 2004 Jan;444(1):43-8 [14569398.001]
  • [Cites] Arch Pathol Lab Med. 2004 Jan;128(1):68-70 [14692808.001]
  • [Cites] Lancet. 2003 Nov 15;362(9396):1612-6 [14630441.001]
  • [Cites] Semin Cancer Biol. 2002 Apr;12(2):113-20 [12027583.001]
  • [Cites] J Pathol. 2003 Nov;201(3):355-62 [14595746.001]
  • [Cites] Virology. 2003 Oct 25;315(2):409-14 [14585344.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1418-28 [14576474.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):605-21, xi [14567020.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12032-7 [11572935.001]
  • [Cites] Gene. 2001 Aug 8;273(2):141-61 [11595161.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1245-50 [11571739.001]
  • [Cites] Br J Cancer. 2001 Sep 14;85(6):863-8 [11556838.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6201-12 [11507073.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5727-30 [11479207.001]
  • [Cites] Surg Oncol. 1998 Jul-Aug;7(1-2):5-12 [10421502.001]
  • [Cites] Cancer. 1999 Jun 15;85(12):2570-6 [10375104.001]
  • [Cites] J Pathol. 1998 Nov;186(3):300-5 [10211120.001]
  • [Cites] J Surg Oncol. 1999 Jan;70(1):6-12 [9989414.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):367-71 [9927048.001]
  • [Cites] Am J Respir Cell Mol Biol. 1998 Nov;19(5):738-46 [9806738.001]
  • [Cites] Curr Opin Cell Biol. 1998 Apr;10(2):220-31 [9561846.001]
  • [Cites] Int J Cancer. 1998 Feb 9;75(4):649-53 [9466670.001]
  • [Cites] J Pathol. 1997 Jan;181(1):67-74 [9072005.001]
  • [Cites] Int J Cancer. 1997 Sep 17;72(6):1034-44 [9378538.001]
  • [Cites] Hum Pathol. 1997 Jun;28(6):641-5 [9190996.001]
  • [Cites] Hum Pathol. 1997 Jan;28(1):84-90 [9013837.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5334-8 [8968079.001]
  • [Cites] J Pathol. 1996 Feb;178(2):151-60 [8683381.001]
  • [Cites] Curr Opin Cell Biol. 2000 Apr;12(2):250-6 [10712922.001]
  • [Cites] Respiration. 2000;67(1):36-40 [10705260.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3508-15 [10589765.001]
  • [Cites] Eur Respir J. 2006 Jun;27(6):1086-95 [16540497.001]
  • [Cites] Acta Oncol. 2006;45(4):449-53 [16760181.001]
  • [Cites] Lung Cancer. 2006 May;52(2):189-97 [16563560.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):2970-9 [16540645.001]
  • [Cites] Lung Cancer. 2006 Feb;51(2):207-15 [16384623.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):447-53 [16428485.001]
  • [Cites] Diagn Cytopathol. 2005 Nov;33(5):332-7 [16240397.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7444-53 [16243818.001]
  • [Cites] Lung Cancer. 2005 Nov;50(2):189-98 [16043260.001]
  • [Cites] Breast Cancer Res Treat. 2005 Nov;94(1):71-80 [16142438.001]
  • [Cites] Lung Cancer. 2005 Oct;50(1):83-6 [15951053.001]
  • [Cites] Semin Oncol. 2005 Jun;32(3):336-50 [15988688.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5256-62 [15958571.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2427-33 [15830375.001]
  • [Cites] Mol Cancer Ther. 2005 May;4(5):835-42 [15897248.001]
  • [Cites] Lung Cancer. 2005 May;48(2):211-6 [15829320.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2602-9 [15805256.001]
  • [Cites] Clin Exp Metastasis. 2004;21(5):469-76 [15672872.001]
  • [Cites] Carcinogenesis. 2005 Jan;26(1):17-25 [15447976.001]
  • [Cites] J Pathol. 1992 May;167(1):1-4 [1320670.001]
  • [Cites] Oncogene. 1991 Nov;6(11):2005-11 [1658707.001]
  • [Cites] Cell. 1992 Apr 3;69(1):11-25 [1555235.001]
  • [Cites] Clin Exp Immunol. 1991 Jan;83(1):85-91 [1846329.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5410-6 [1913660.001]
  • [Cites] Science. 1991 Mar 22;251(5000):1451-5 [2006419.001]
  • [Cites] J Clin Invest. 1991 Jan;87(1):1-5 [1985087.001]
  • [Cites] Br J Cancer. 1990 Jun;61(6):924-6 [2372497.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7479-85 [15492273.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1157-66 [15451223.001]
  • [Cites] Clin Cancer Res. 2004 Sep 1;10(17):5907-18 [15355924.001]
  • [Cites] Cancer Immunol Immunother. 2004 Oct;53(10):904-10 [15069585.001]
  • [Cites] Oncogene. 2004 Aug 26;23(39):6672-6 [15221014.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 18;96(16):1219-30 [15316057.001]
  • [Cites] Lung Cancer. 2004 Aug;45 Suppl 1:S125-7 [15261445.001]
  • [Cites] Lancet Oncol. 2004 Jun;5(6):354-62 [15172356.001]
  • [Cites] Semin Cancer Biol. 2004 Aug;14(4):231-43 [15219616.001]
  • [Cites] Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):3937-42 [15217923.001]
  • [Cites] Chest. 2004 May;125(5):1843-52 [15136399.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3572-9 [15150114.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3474-8 [15150100.001]
  • [Cites] Thorax. 2004 May;59(5):428-33 [15115874.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1807-15 [15111327.001]
  • [Cites] Lung Cancer. 2004 May;44(2):159-65 [15084380.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Apr;286(4):L859-65 [14617514.001]
  • [Cites] Int J Cancer. 2004 May 1;109(5):786-92 [14999791.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):849-59 [14871960.001]
  • [Cites] Respir Med. 2001 Jul;95(7):588-93 [11453316.001]
  • [Cites] Histopathology. 2001 Jun;38(6):535-41 [11422497.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jun;127(2):93-110 [11425448.001]
  • [Cites] Int J Oncol. 2001 May;18(5):1093-8 [11295061.001]
  • [Cites] Hum Pathol. 2003 Aug;34(8):749-55 [14506634.001]
  • [Cites] Thorax. 2003 Sep;58(9):809-13 [12947146.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):3080-97 [12912960.001]
  • [Cites] J Pathol. 2003 Jul;200(4):429-47 [12845611.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2108-13 [12796375.001]
  • [Cites] Br J Cancer. 2003 May 19;88(10):1553-9 [12771921.001]
  • [Cites] Int J Biochem Cell Biol. 2003 Aug;35(8):1198-209 [12757757.001]
  • [Cites] J Natl Cancer Inst. 2003 Apr 16;95(8):598-605 [12697852.001]
  • [Cites] J Pathol. 2003 Apr;199(4):479-87 [12635139.001]
  • [Cites] Thorax. 2003 Mar;58(3):198-203 [12612292.001]
  • [Cites] Chest. 2003 Feb;123(2):551-61 [12576380.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):150-8 [12548160.001]
  • [Cites] Mol Cancer Ther. 2002 Jul;1(9):687-94 [12479365.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6065-9 [12414630.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):4963-7 [12208747.001]
  • [Cites] Mod Pathol. 2002 Aug;15(8):818-25 [12181266.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4169-75 [12154012.001]
  • [Cites] Am J Clin Pathol. 2002 Jul;118(1):85-92 [12109861.001]
  • [Cites] Carcinogenesis. 2002 Jun;23(6):1017-24 [12082024.001]
  • [Cites] Exp Cell Res. 2001 Mar 10;264(1):169-84 [11237532.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] Clin Exp Metastasis. 2002;19(2):135-44 [11964077.001]
  • [Cites] Oncogene. 2002 Apr 25;21(18):2896-900 [11973650.001]
  • [Cites] Nat Rev Immunol. 2002 Mar;2(3):175-84 [11913068.001]
  • [Cites] Thorax. 2002 Apr;57(4):353-6 [11923556.001]
  • [Cites] Oncogene. 2002 Feb 21;21(9):1434-42 [11857086.001]
  • [Cites] Am J Respir Cell Mol Biol. 2002 Feb;26(2):189-93 [11804869.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1405-12 [11684957.001]
  • [Cites] Diagn Cytopathol. 2001 Oct;25(4):203-7 [11599101.001]
  • [Cites] Am J Clin Pathol. 2007 May;127(5):752-9 [17439834.001]
  • [Cites] Int J Cancer. 2007 Jan 15;120(2):215-23 [17131333.001]
  • [Cites] Lung Cancer. 2006 Dec;54(3):309-17 [16996643.001]
  • [Cites] Acta Cytol. 2006 Nov-Dec;50(6):603-7 [17152269.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Jan;59(1):149-50 [16636799.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5944-50 [17062665.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Oct 1;170(1):9-15 [16965949.001]
  • [Cites] Neoplasia. 2006 Jul;8(7):551-9 [16867217.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4225-31 [16857795.001]
  • [Cites] Virchows Arch. 2006 Jul;449(1):31-9 [16541284.001]
  • [Cites] Br J Cancer. 1999 Sep;81(1):54-61 [10487612.001]
  • [Cites] Diagn Cytopathol. 1998 Feb;18(2):141-9 [9484644.001]
  • [Cites] J Pathol. 1999 Sep;189(1):72-8 [10451491.001]
  • [Cites] Clin Exp Metastasis. 1998 Aug;16(6):529-39 [9872600.001]
  • [Cites] Int J Cancer. 1998 Apr 13;76(2):240-9 [9537587.001]
  • [Cites] Am J Pathol. 1998 Feb;152(2):333-40 [9466557.001]
  • [Cites] Virchows Arch. 1999 Jul;435(1):8-12 [10431840.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40 [8552591.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):10854-8 [7479897.001]
  • [Cites] Acta Cytol. 1995 Jul-Aug;39(4):613-22 [7543232.001]
  • [Cites] Mol Pharmacol. 1994 Sep;46(3):437-44 [7935323.001]
  • [Cites] Oncogene. 1995 Aug 3;11(3):511-5 [7630635.001]
  • [Cites] Cancer Res. 1995 Mar 15;55(6):1227-31 [7882313.001]
  • [Cites] Cancer Immunol Immunother. 1994 Dec;39(6):347-59 [8001022.001]
  • [Cites] Curr Probl Surg. 1993 Oct;30(10):921-1012 [8404013.001]
  • (PMID = 19662202.001).
  • [Journal-full-title] Biomarker insights
  • [ISO-abbreviation] Biomark Insights
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2717840
  • [Keywords] NOTNLM ; hallmarks of cancer / high throughput / malignant mesothelioma / metastasis
  •  go-up   go-down


57. Pass HI, Carbone M: Current status of screening for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg; 2009;21(2):97-104
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current status of screening for malignant pleural mesothelioma.
  • Malignant mesothelioma is characterized by its association with asbestos, its long latency period, and the propensity for the diagnosis to be obtained in the later stages of the disease.
  • Because the high-risk cohorts for mesothelioma are fairly well defined by the association with asbestos, and the exposure is usually in the workplace, it is hypothesized that early detection of the disease could (1) find patients at an earlier, more treatable stage and (2) result in prolonged survival over the present median 12 months from the start of therapy.
  • Many studies have used standard chest X-ray to characterize changes associated with asbestos-exposed individuals, but the insensitivity of X-ray in screening patients with mesothelioma has never supported the wide-scale adaptation of such an effort.
  • Most recently, serum biomarkers with the potential to discriminate asbestos-exposed, non-cancer-bearing individuals from those with mesothelioma have been investigated both at single institutions and with multi-institutional-blinded trials.
  • These markers, including soluble mesothelin-related protein, osteopontin, and megakaryocyte potentiating factor, may, in the future, be incorporated into a screening algorithm for high-risk asbestos-exposed individuals to help monitor these cohorts in a noninvasive fashion and guide the use of computerized tomography.
  • [MeSH-major] Biomarkers, Tumor / blood. Mass Screening / methods. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Asbestos / adverse effects. GPI-Linked Proteins. Humans. Membrane Glycoproteins / blood. Occupational Exposure. Osteopontin / blood. Patient Selection. Predictive Value of Tests. Risk Assessment. Risk Factors

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19822280.001).
  • [ISSN] 1043-0679
  • [Journal-full-title] Seminars in thoracic and cardiovascular surgery
  • [ISO-abbreviation] Semin. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / SPP1 protein, human; 0 / mesothelin; 106441-73-0 / Osteopontin; 1332-21-4 / Asbestos
  • [Number-of-references] 70
  •  go-up   go-down


58. Scherpereel A, Grigoriu B, Conti M, Gey T, Grégoire M, Copin MC, Devos P, Chahine B, Porte H, Lassalle P: Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med; 2006 May 15;173(10):1155-60
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
  • BACKGROUND: Diagnosis of malignant pleural mesothelioma is a challenging issue.
  • Potential markers in mesothelioma diagnosis include soluble mesothelin-related peptides (SMRPs) and osteopontin, but no subsequent validation has been published yet.
  • METHODS: We prospectively evaluated SMRPs in serum and pleural effusion from patients with mesothelioma (n = 74), pleural metastasis of carcinomas (n = 35), or benign pleural lesions associated with asbestos exposure (n = 28), recruited when first suspected for mesothelioma.
  • FINDINGS: Mean serum SMRP level was higher in patients with mesothelioma (2.05 +/- 2.57 nM/L [median +/- interquartile range]) than in patients with metastasis (1.02 +/- 1.79 nM/L) or benign lesions (0.55 +/- 0.59 nM/L).
  • The area under the receiver operating characteristic curve (AUC) for serum SMRP was 0.872 for differentiating mesothelioma and benign lesions, cut-off = 0.93 nM/L (sensitivity = 80%, specificity = 82.6%).
  • The AUC for serum SMRP differentiating metastasis and mesothelioma was 0.693, cut-off = 1.85 nM/L (sensitivity = 58.3%, specificity = 73.3%).
  • SMRP values in pleural fluid were higher than in serum in all groups (mesothelioma: 46.1 +/- 83.2 nM/L; benign lesions: 6.4 +/- 11.1 nM/L; metastasis: 6.36 +/- 21.73 nM/L).
  • The AUC for pleural SMRP-differentiating benign lesions and mesothelioma was 0.831, cut-off = 10.4 nM/L (sensitivity = 76.7%, specificity = 76.2%).
  • The AUC for pleural SMRP-differentiating metastasis and mesothelioma was 0.793.
  • INTERPRETATION: We show that SMRPs may be a promising marker for mesothelioma diagnosis when measured either in serum or pleural fluid.
  • The diagnostic value of SMRPs was similar in both types of samples, but pleural fluid SMRPs may better discriminate mesothelioma from pleural metastasis.
  • [MeSH-major] Asbestosis / pathology. Membrane Glycoproteins / metabolism. Mesothelioma / pathology. Pleural Effusion, Malignant / diagnosis. Pleural Neoplasms / pathology. Sialoglycoproteins / metabolism

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16456138.001).
  • [ISSN] 1073-449X
  • [Journal-full-title] American journal of respiratory and critical care medicine
  • [ISO-abbreviation] Am. J. Respir. Crit. Care Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 0 / mesothelin; 106441-73-0 / Osteopontin
  •  go-up   go-down


59. Mensi C, Garberi A, Bordini L, Sieno C, Riboldi L: Asbestos-related diseases in entertainment workers. Med Lav; 2010 Nov-Dec;101(6):416-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asbestos-related diseases in entertainment workers.
  • OBJECTIVES: To investigate asbestos exposure in 4 patients (3 cases of malignant mesothelioma and 1 case ofpleural plagues) previously employed in the entertainment business.
  • Information regarding exposure to asbestos (occupational, environmental, and familial) was collected through a standardized questionnaire administered to the patients by an occupational physician.
  • RESULTS AND CONCLUSION: The presence of asbestos in the building structures and its use were described by all patients.
  • The presence of asbestos in public buildings used for entertainment such as cinemas and theatres was in fact confirmed by the Occupational Health Services of the Local Heath Unit.
  • An occupational aetiology was recognised in all the cases mentioned above, thus leading to the identification of an atypical occupational sector at risk in the past for asbestos exposure,
  • [MeSH-major] Air Pollutants, Occupational / adverse effects. Asbestos / adverse effects. Mesothelioma / etiology. Occupational Diseases / etiology. Pleural Neoplasms / etiology. Public Facilities
  • [MeSH-minor] Aged. Asbestos, Crocidolite / adverse effects. Asbestosis / etiology. Calcinosis / etiology. Female. Humans. Male. Manufactured Materials / adverse effects. Middle Aged. Mineral Fibers / adverse effects. Pleural Diseases / etiology. Protective Clothing / adverse effects. Time Factors

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21141346.001).
  • [ISSN] 0025-7818
  • [Journal-full-title] La Medicina del lavoro
  • [ISO-abbreviation] Med Lav
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational; 0 / Mineral Fibers; 12001-28-4 / Asbestos, Crocidolite; 1332-21-4 / Asbestos
  •  go-up   go-down


60. Cvitanović S, Ivancević Z, Capkun V, Tenzera-Taslak G: [Incidence of malignant pleural mesothelioma in Split-Dalmatia County]. Arh Hig Rada Toksikol; 2009 Nov;60 Suppl:31-9
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Incidence of malignant pleural mesothelioma in Split-Dalmatia County].
  • Between 2001 and 2005, 1150 patients with respiratory symptoms were admitted to our Pneumology Clinic whose workplace or residence could involve exposure to asbestos One hundred and twenty (10.4%) patients were confirmed a disease of the lung and/or pleura which could have been asbestos-related.
  • A follow-up of these patients showed that 52 of 120 (43.3%) developed malignant pleural mesothelioma (MPM), but it was also found in 12 of 1030 (1.1%) patients without an asbestos-related disease.
  • Fifty-two (81.2%) were professionally or residentially exposed to asbestos.
  • This distribution of MPM may be related to the strong shipbuilding industry and other asbestos-related industries in this part of the country.
  • [MeSH-major] Asbestos / adverse effects. Mesothelioma / epidemiology. Pleural Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20853776.001).
  • [ISSN] 0004-1254
  • [Journal-full-title] Arhiv za higijenu rada i toksikologiju
  • [ISO-abbreviation] Arh Hig Rada Toksikol
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


61. McCoy MJ, Nowak AK, Lake RA: Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma. Tissue Antigens; 2009 Jul;74(1):1-10
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoimmunotherapy: an emerging strategy for the treatment of malignant mesothelioma.
  • Whether the immune system can recognize malignant and premalignant cells and eliminate them to prevent the development of cancer is still a matter of open debate, but in our view, the balance of evidence favours this concept.
  • Malignant mesothelioma has traditionally been considered a relatively non-immunogenic cancer.
  • However, mesothelioma cells do express a set of well-defined tumour antigens that have been shown to engage with the host immune system.
  • Mesothelioma should therefore be considered a target for immunotherapy.
  • A variety of anticancer immunotherapies have been investigated in mesothelioma and in other malignancies, although these have been largely ineffective when used in isolation.
  • Here, we discuss the rationale behind combining these two, long considered antagonistic, treatment options in the context of malignant mesothelioma.
  • [MeSH-major] Antigens, Neoplasm / immunology. Antineoplastic Agents / therapeutic use. Immunosuppression. Mesothelioma / therapy. Neoplasms, Mesothelial / therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19422663.001).
  • [ISSN] 1399-0039
  • [Journal-full-title] Tissue antigens
  • [ISO-abbreviation] Tissue Antigens
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Cytokines
  • [Number-of-references] 93
  •  go-up   go-down


62. Tomasetti M, Amati M, Santarelli L, Alleva R, Neuzil J: Malignant mesothelioma: biology, diagnosis and therapeutic approaches. Curr Mol Pharmacol; 2009 Jun;2(2):190-206
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma: biology, diagnosis and therapeutic approaches.
  • Malignant mesothelioma (MM) is an aggressive neoplasm of serosal cavities, which is resistant to conventional therapy, with patient survival from presentation of <12 months.
  • Although the main risk factor is asbestos exposure, other factors, Simian virus 40 infection and inheritance of susceptibility genes, likely play a role.
  • Asbestos-related carcinogenic process is primarily based on the interaction between susceptibility (genetic and acquired) and exposure to carcinogenic environmental agents.
  • Asbestos-induced carcinogenesis includes generation of reactive oxygen species, which induce DNA strand breaks and oxidant-induced base modifications to DNA.
  • Several programs have been used to screen asbestos-exposed individuals for lung and pleural disease.
  • [MeSH-major] Mesothelioma / diagnosis
  • [MeSH-minor] Asbestos / toxicity. Carcinogens / toxicity. DNA Damage. Humans. Mitogen-Activated Protein Kinases / metabolism. NF-kappa B / metabolism. Simian virus 40 / physiology. Transcription Factor AP-1 / metabolism

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021458.001).
  • [ISSN] 1874-4702
  • [Journal-full-title] Current molecular pharmacology
  • [ISO-abbreviation] Curr Mol Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Carcinogens; 0 / NF-kappa B; 0 / Transcription Factor AP-1; 1332-21-4 / Asbestos; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  • [Number-of-references] 180
  •  go-up   go-down


63. Nesti M, Marinaccio A, Gennaro V, Gorini G, Mirabelli D, Mensi C, Merler E, Montanaro F, Musti M, Pannelli F, Romanelli A, Tumino R, ReNaM Working Group: Epidemiologic surveillance for primary prevention of malignant mesothelioma: the Italian experience. Med Lav; 2005 Jul-Aug;96(4):338-46
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiologic surveillance for primary prevention of malignant mesothelioma: the Italian experience.
  • BACKGROUND: The Italian National Mesothelioma Registry (ReNaM) was set up at the National Institute for Occupational Safety and Health (ISPESL) to estimate Italian incidence of malignant mesothelioma (MM), define modalities of asbestos exposures, assess impact and diffusion of MM, identify underestimated sources of environmental contamination.
  • Exposure modalities are classified by industrial hygienists, evaluating whether work, private life or any particular environmental condition could have involved asbestos exposure.
  • Pleural mesothelioma affected 94% cases, pleural/peritoneal ratio was 16:1.
  • CONCLUSIONS: Despite some ReNam's limitations, identification of MM cases and analysis of modality of exposure, with standardized criteria, are a fundamental tool for primary prevention of asbestos related diseases.
  • [MeSH-major] Mesothelioma / prevention & control. Occupational Diseases / prevention & control. Peritoneal Neoplasms / prevention & control. Pleural Neoplasms / prevention & control. Population Surveillance / methods. Primary Prevention / methods
  • [MeSH-minor] Asbestos / adverse effects. Carcinogens / toxicity. Female. Humans. Italy / epidemiology. Male. Occupational Exposure / adverse effects. Practice Guidelines as Topic. Retrospective Studies. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16457430.001).
  • [ISSN] 0025-7818
  • [Journal-full-title] La Medicina del lavoro
  • [ISO-abbreviation] Med Lav
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Carcinogens; 1332-21-4 / Asbestos
  •  go-up   go-down


64. Harb A, King E, Lloyd H, Harb Z, Payne JG: Primary omental mesothelioma: a rare but important differential diagnosis in previous asbestos exposure. J Gastrointest Surg; 2010 Feb;14(2):423-5
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary omental mesothelioma: a rare but important differential diagnosis in previous asbestos exposure.
  • Primary omental mesothelioma is a malignant tumour of the mesothelial cells of the omentum, related to asbestos exposure.
  • We present a review of the related literature and report on a fatal case of primary omental mesothelioma in a 70 year old man, presenting with a painful abdominal mass.
  • [MeSH-major] Asbestosis. Mesothelioma / diagnosis. Occupational Exposure. Omentum / pathology. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Aged. Asbestos / adverse effects. Diagnosis, Differential. Fatal Outcome. Humans. Male

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1031-51 [12883236.001]
  • [Cites] Surg Today. 2004;34(9):780-3 [15338355.001]
  • [Cites] AJR Am J Roentgenol. 1984 Nov;143(5):1075-7 [6333150.001]
  • [Cites] Zentralbl Gynakol. 1983;105(9):598-601 [6880476.001]
  • (PMID = 19424765.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


65. Maeda M, Miura Y, Nishimura Y, Murakami S, Hayashi H, Kumagai N, Hatayama T, Katoh M, Miyahara N, Yamamoto S, Fukuoka K, Kishimoto T, Nakano T, Otsuki T: Immunological changes in mesothelioma patients and their experimental detection. Clin Med Circ Respirat Pulm Med; 2008;2:11-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunological changes in mesothelioma patients and their experimental detection.
  • It is common knowledge that asbestos exposure causes asbestos-related diseases such as asbestosis, lung cancer and malignant mesothelioma (MM) not only in people who have handled asbestos in the work environment, but also in residents living near factories that handle asbestos.
  • We focused on the immunological effects of asbestos and silica on the human immune system.
  • Analysis of the immunological effects of asbestos may help our understanding of the biological effects of asbestos.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21157517.001).
  • [ISSN] 1178-1157
  • [Journal-full-title] Clinical medicine. Circulatory, respiratory and pulmonary medicine
  • [ISO-abbreviation] Clin Med Circ Respirat Pulm Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2990230
  • [Keywords] NOTNLM ; asbestos / chrysotile / immunology / mesothelioma
  •  go-up   go-down


66. Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K: Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. Lung Cancer; 2008 Aug;61(2):235-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
  • Soluble mesothelin-related protein (SMRP) in serum is potentially a sensitive marker of malignant mesothelioma (MM) diagnosis and progression, and may be useful as screening marker.
  • Levels of SMRP, CA125 and CYFRA 21-1 in pre-diagnostic (1-30 years) serum samples from 47 mesothelioma cases and 141 matched controls were analysed.
  • The association between biomarker level and mesothelioma risk and survival was analysed, adjusting for asbestos exposure.
  • Survival related to tumor mesothelin expression, age, sex, histological type, location, asbestos exposure and pre-clinical SMRP was analysed.
  • There was no significant association between biomarker levels and mesothelioma risk when analysed as continuous variables or as tertiles.
  • Biomarker levels <10, 10-19 and >or=20 years before diagnosis were not significantly associated to mesothelioma risk.
  • Mesothelin expression in <50% of tumor cells was a significant negative prognostic marker in all cases of malignant mesothelioma (median survival=6 months vs. 12 months, hazard ratio (HR)=2.49, 95%CI 1.17-5.27), and also when only epithelial mesothelioma was analysed (median=6 months vs. 14 months, HR=2.36, 95%CI 1.07-5.22).
  • High age (>65 years) was an independent negative prognostic factor that was related to both mesothelin expression and asbestos exposure.
  • Mesothelioma of the epithelial type of the peritoneum had a significantly longer survival than epithelial type in pleura and was also related to mesothelin expression.
  • [MeSH-major] Antigens, Neoplasm / blood. Biomarkers, Tumor / blood. Keratins / blood. Membrane Glycoproteins / blood. Mesothelioma / diagnosis. Peritoneal Neoplasms / diagnosis. Pleural Neoplasms / diagnosis. Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Age Factors. Asbestos / adverse effects. Case-Control Studies. Child. Child, Preschool. Female. GPI-Linked Proteins. Humans. Infant. Keratin-19. Male. Occupational Exposure / adverse effects. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281122.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Keratin-19; 0 / Membrane Glycoproteins; 0 / NBR1 protein, human; 0 / Proteins; 0 / antigen CYFRA21.1; 0 / mesothelin; 1332-21-4 / Asbestos; 68238-35-7 / Keratins
  •  go-up   go-down


67. Antonescu-Turcu AL, Schapira RM: Parenchymal and airway diseases caused by asbestos. Curr Opin Pulm Med; 2010 Mar;16(2):155-61
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parenchymal and airway diseases caused by asbestos.
  • PURPOSE OF REVIEW: The extensive industrial use of asbestos for many decades has been linked to development of benign and malignant pleuropulmonary disease.
  • This review summarizes newer evidence and ongoing controversies that exist in the literature regarding asbestos-related parenchymal and airway diseases.
  • RECENT FINDINGS: Asbestosis represents a significant respiratory problem despite the improvement in the workplace hygiene and a decrease in use of asbestos.
  • The role of asbestos exposure alone as a cause of chronic airway obstruction remains uncertain.
  • The relationship between lung cancer and asbestos exposure alone and in combination with smoking has also been investigated.
  • The benefit of screening for asbestos-related pleuropulmonary disease remains uncertain as does the use of computed tomography scanning for the purpose of screening.
  • SUMMARY: Future studies will help clarify the clinical issues and shape screening strategies for asbestos-exposed individuals.
  • [MeSH-major] Asbestos / adverse effects. Asbestosis / etiology. Lung Diseases / chemically induced
  • [MeSH-minor] Humans. Lung Diseases, Obstructive / chemically induced. Lung Diseases, Obstructive / radiography. Lung Neoplasms / chemically induced. Lung Neoplasms / radiography. Mesothelioma / chemically induced. Mesothelioma / radiography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20104177.001).
  • [ISSN] 1531-6971
  • [Journal-full-title] Current opinion in pulmonary medicine
  • [ISO-abbreviation] Curr Opin Pulm Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  • [Number-of-references] 34
  •  go-up   go-down


68. Creaney J, Musk AW, Robinson BW: Sensitivity of urinary mesothelin in patients with malignant mesothelioma. J Thorac Oncol; 2010 Sep;5(9):1461-6
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sensitivity of urinary mesothelin in patients with malignant mesothelioma.
  • INTRODUCTION: Malignant mesothelioma (MM) is an aggressive, uniformly fatal tumor usually caused by exposure to asbestos.
  • As urine is less complex and less invasive to collect than serum and may be a more acceptable specimen for large-scale screening studies of asbestos-exposed individuals, we determined whether the sensitivity and specificity for MM could be improved by measuring soluble mesothelin in the urine.
  • METHODS: Soluble mesothelin concentrations were determined using the MESOMARK assay in concurrent serum and urine samples from 70 patients with pleural MM, 111 patients with asbestos-related lung or pleural disease, and 45 patients with benign nonasbestos-related lung and pleural disease.
  • [MeSH-major] Asbestos / adverse effects. Biomarkers, Tumor / urine. Membrane Glycoproteins / urine. Mesothelioma / urine. Pleural Neoplasms / urine

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20815094.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 1332-21-4 / Asbestos; AYI8EX34EU / Creatinine
  •  go-up   go-down


69. Riehemann K, Schmitt O, Ehlers EM: The effects of thermochemotherapy using cyclophosphamide plus hyperthermia on the malignant pleural mesothelioma in vivo. Ann Anat; 2005 Jul;187(3):215-23
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effects of thermochemotherapy using cyclophosphamide plus hyperthermia on the malignant pleural mesothelioma in vivo.
  • The human malignant pleural mesothelioma is related to the use of asbestos in the majority of cases.
  • Though the use of asbestos has been prohibited since the 1990s, the incidence of pleural mesothelioma is still increasing because of a latency period of at least 20 years.
  • This study investigated the benefit of single therapy with cyclophosphamide or hyperthermia or the combination of both on cells of a human pleural mesothelioma cell line, xenotransplanted subcutaneously in the paw of mice.
  • This study shows promising results in the treatment of malignant pleural mesothelioma.
  • [MeSH-major] Cyclophosphamide / therapeutic use. Hyperthermia, Induced. Mesothelioma / therapy. Pleural Neoplasms / therapy

  • Genetic Alliance. consumer health - Malignant hyperthermia.
  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16130821.001).
  • [ISSN] 0940-9602
  • [Journal-full-title] Annals of anatomy = Anatomischer Anzeiger : official organ of the Anatomische Gesellschaft
  • [ISO-abbreviation] Ann. Anat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


70. Becklake MR, Bagatin E, Neder JA: Asbestos-related diseases of the lungs and pleura: uses, trends and management over the last century. Int J Tuberc Lung Dis; 2007 Apr;11(4):356-69
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asbestos-related diseases of the lungs and pleura: uses, trends and management over the last century.
  • Asbestos is a descriptive term for a group of naturally occurring minerals known to mankind since ancient times.
  • The main types of asbestos (chrysotile, and the amphiboles crocidolite and amosite) differ in chemical structure, biopersistence in human tissue and toxicity.
  • As its ill-health effects, both non-malignant (fibrosis of the lungs or asbestosis; pleural effusion, plaques and thickening) and malignant (mesothelioma, lung and other cancers), became evident, public pressure rose to control its use.
  • The last decades of the last century saw decreases in exposure and rates of asbestosis in industrialised and in some less-industrialised countries, where pleural plaques and malignant mesothelioma are currently the most frequent manifestations of asbestos exposure.
  • Longer follow-up of asbestos-exposed cohorts in mining and manufacturing has also strengthened the evidence of a fibre gradient in toxicity, with chrysotile exhibiting lower toxicity than the amphiboles, and amosite lower toxicity than crocidolite.
  • The last decades of the twentieth century saw stabilisation and/or declines in mesothelioma rates in several industrialised countries.
  • Management of asbestos-related disease in the workplace requires collaboration between workers and unions (responsible for monitoring workplace dust levels, to which they must have access) and companies (responsible for engineering controls), reinforced by appropriate government regulations and by community support.
  • [MeSH-minor] Humans. Lung Neoplasms / epidemiology. Lung Neoplasms / etiology. Mesothelioma / epidemiology. Mesothelioma / etiology. Mineral Fibers. Pleural Diseases / therapy. Workplace

  • MedlinePlus Health Information. consumer health - Asbestos.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Tuberc Lung Dis. 2008 Jul;12(7):824
  • (PMID = 17394680.001).
  • [ISSN] 1027-3719
  • [Journal-full-title] The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
  • [ISO-abbreviation] Int. J. Tuberc. Lung Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Mineral Fibers
  • [Number-of-references] 70
  •  go-up   go-down


71. Witherby SM, Butnor KJ, Grunberg SM: Malignant mesothelioma following thoracic radiotherapy for lung cancer. Lung Cancer; 2007 Sep;57(3):410-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma following thoracic radiotherapy for lung cancer.
  • Although some of these malignancies may be related to common environmental exposures, a significant number are considered to be therapy-related.
  • Pleural malignant mesothelioma is a neoplasm that may be related to asbestos exposure or radiation exposure.
  • Previous reports of pleural mesothelioma as a second malignancy have tended to follow radiotherapy for extra-thoracic malignancies such as Hodgkin's disease, breast cancer and Wilms' tumor.
  • We report the case of a 66-year-old woman with no prior asbestos exposure who developed pleural mesothelioma 17 years after pneumonectomy and adjuvant radiation therapy for non-small cell lung cancer.
  • Secondary malignancies such as mesothelioma should be considered in patients who develop unexplained symptoms even long after treatment of a primary tumor.
  • [MeSH-major] Lung Neoplasms / radiotherapy. Mesothelioma / diagnosis. Neoplasms, Radiation-Induced / diagnosis. Neoplasms, Second Primary / diagnosis. Pleural Neoplasms / diagnosis


72. Canti Z, Scillia R, Cantoni S, Mensi C: [Malignant mesothelioma of the pleura in a truck driver]. Med Lav; 2007 May-Jun;98(3):216-20
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant mesothelioma of the pleura in a truck driver].
  • BACKGROUND: Among the responsibilities of the health operators in the occupational health and safety services of the local health units in Lombardy (Italy) is the administration of standardized questionnaires for the investigation of possible occupational exposure to asbestos fibres in subjects diagnosed with malignant mesothelioma.
  • OBJECTIVES: To describe a case of malignant mesothelioma in a truck driver suspected of being occupationally exposed to asbestos during the course of administration of the questionnaire.
  • METHODS: Analysis of the literature regarding asbestos contamination of truck cabs.
  • Some years ago Italian authors described a case of asbestosis in a truck-driver and findings of pollution by asbestos fibres in the cabs of some models of trucks.
  • RESULTS: The subject had worked for more than 30 years as a truck driver operating on long distances on truck models described in literature as contaminated by asbestos fibres.
  • He had not transported materials made of asbestos, and had not carried out maintenance on the trucks, nor had he any non-occupational sources of exposure to asbestos.
  • Thus the mesothelioma was related to occupational exposure and procedures were initiated for reporting a suspected occupational disease.
  • [MeSH-major] Asbestos / adverse effects. Automobile Driving. Mesothelioma / etiology. Mineral Fibers / adverse effects. Motor Vehicles. Occupational Diseases / etiology. Pleural Neoplasms / etiology


73. Otsuki T, Maeda M, Murakami S, Hayashi H, Miura Y, Kusaka M, Nakano T, Fukuoka K, Kishimoto T, Hyodoh F, Ueki A, Nishimura Y: Immunological effects of silica and asbestos. Cell Mol Immunol; 2007 Aug;4(4):261-8
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunological effects of silica and asbestos.
  • Silicosis patients (SILs) and patients who have been exposed to asbestos develop not only respiratory diseases but also certain immunological disorders.
  • In addition, malignant complications such as lung cancer and malignant mesothelioma often occur in patients exposed to asbestos, and may be involved in the reduction of tumor immunity.
  • A brief summary of our investigations related to the immunological effects of silica/asbestos is presented.
  • Recent advances in immunomolecular studies led to detailed analyses of the immunological effects of asbestos and silica.
  • Both affect immuno-competent cells and these effects may be associated with the pathophysiological development of complications in silicosis and asbestos-exposed patients such as the occurrence of autoimmune disorders and malignant tumors, respectively.
  • In particular, as the incidence of asbestos-related malignancies is increasing and such malignancies have been a medical and social problem since the summer of 2005 in Japan, efforts should be focused on developing a cure for these diseases to eliminate nationwide anxiety.
  • [MeSH-major] Asbestos / immunology. Silicon Dioxide / immunology

  • MedlinePlus Health Information. consumer health - Asbestos.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17764616.001).
  • [ISSN] 1672-7681
  • [Journal-full-title] Cellular & molecular immunology
  • [ISO-abbreviation] Cell. Mol. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Autoantibodies; 1332-21-4 / Asbestos; 7631-86-9 / Silicon Dioxide
  • [Number-of-references] 72
  •  go-up   go-down


74. Amati M, Tomasetti M, Scartozzi M, Mariotti L, Ciuccarelli M, Valentino M, Governa M, Santarelli L: [Biomarkers for prevention and early diagnosis of malignant pleural mesothelioma]. G Ital Med Lav Ergon; 2007 Jul-Sep;29(3 Suppl):335-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biomarkers for prevention and early diagnosis of malignant pleural mesothelioma].
  • Improved detection methods for diagnosis of asymptomatic malignant pleural mesothelioma (MPM) are essential for an early and reliable detection and treatment of this disease.
  • 94 asbestos-exposed subjects, 22 patients with MM, and 54 healthy subjects were recruited for evaluation of the significance of 8-hydroxy-2'-deoxy-guanosine (80HdG) in white blood cells and plasma concentrations of soluble mesothelin-related peptides (SMRPs), angiogenic factors (PDGFbeta, HGF, bFGF, VEGFbeta), and matrix proteases (MMP2, MMP9, TIMP1, TIMP2) for potential early detection of MM.
  • The area under ROC curves (AUC) indicates that 80HdG levels can discriminate asbestos-exposed subjects from controls but not from MPM patients.
  • Significant AUC values were found for SMRP discriminating asbestos-exposed subjects from MPM patients but not from controls.
  • VEGFbeta can significantly differentiate asbestos-exposed subjects from control and cancer groups.
  • The combination of blood biomarkers and radiographic findings could be used to stratify the risk of mesothelioma in asbestos-exposed populations.
  • [MeSH-major] Biomarkers, Tumor / blood. Mesothelioma / diagnosis. Mesothelioma / prevention & control. Pleural Neoplasms / prevention & control

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18409713.001).
  • [ISSN] 1592-7830
  • [Journal-full-title] Giornale italiano di medicina del lavoro ed ergonomia
  • [ISO-abbreviation] G Ital Med Lav Ergon
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


75. Hasegawa S: [Therapeutic strategies for resectable malignant pleural mesothelioma]. Nihon Geka Gakkai Zasshi; 2009 Nov;110(6):338-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic strategies for resectable malignant pleural mesothelioma].
  • Malignant pleural mesothelioma (MPM) is a rare thoracic malignancy associated with very poor prognosis.
  • The Mesothelioma and Radical Surgery (MARS) trial is a randomized clinical trial seeking to clarify the role of radical surgery in MPM treatment.
  • An all-Japan clinical study of trimodality treatment for MPM is currently underway as a part of a national campaign entitled "Comprehensive Strategy against Asbestos-Related Diseases. "
  • [MeSH-major] Mesothelioma / therapy. Pleural Neoplasms / therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19999568.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


76. Pinton G, Brunelli E, Murer B, Puntoni R, Puntoni M, Fennell DA, Gaudino G, Mutti L, Moro L: Estrogen receptor-beta affects the prognosis of human malignant mesothelioma. Cancer Res; 2009 Jun 1;69(11):4598-604
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen receptor-beta affects the prognosis of human malignant mesothelioma.
  • Malignant pleural mesothelioma is an asbestos-related neoplasm with poor prognosis, refractory to current therapies, the incidence of which is expected to increase in the next decades.
  • Female gender was identified as a positive prognostic factor among other clinical and biological prognostic markers for malignant mesothelioma, yet a role of estrogen receptors (ERs) has not been studied.
  • Our goal was to investigate ERs expression in malignant mesothelioma and to assess whether their expression correlates with prognosis.
  • Multivariate analysis of 78 malignant mesothelioma patients with pathologic stage, histologic type, therapy, sex, and age at diagnosis indicated that ERbeta expression is an independent prognostic factor of better survival.
  • Moreover, studies in vitro confirmed that treatment with 17beta-estradiol led to an ERbeta-mediated inhibition of malignant mesothelioma cell proliferation as well as p21(CIP1) and p27(KIP1) up-regulation.
  • Our data support the notion that ERbeta acting as a tumor suppressor is of high potential relevance to prediction of disease progression and to therapeutic response of malignant mesothelioma patients.
  • [MeSH-major] Estrogen Receptor beta / metabolism. Estrogen Receptor beta / physiology. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis


77. Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, Robinson BW: Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol; 2008 Aug;3(8):851-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
  • INTRODUCTION: There is increasing interest in identifying a blood-based marker for the asbestos-related tumor, malignant mesothelioma.
  • Three potential markers for mesothelioma are mesothelin, megakaryocyte potentiating factor (MPF) and osteopontin.
  • The purpose of the current study was to directly compare these biomarkers in the same sample population, determining their sensitivity and specificity in establishing a diagnosis, and to determine if diagnostic accuracy for mesothelioma is improved by combining the data from all three markers.
  • METHODS: Serum levels of mesothelin, MPF and osteopontin were determined by commercially available assays in 66 samples from patients with pleural malignant mesothelioma, 20 healthy individuals, 21 patients with asbestos-related lung or pleural disease, 30 patients presenting with benign pleural effusions and 30 patients with other malignancies.
  • RESULTS: Serum levels of the three markers were elevated in mesothelioma patients.
  • At a level of specificity of 95% relative to healthy controls and patients with benign asbestos related disease, the sensitivity for mesothelioma was 34% for MPF, 47% for osteopontin and 73% for mesothelin.
  • Osteopontin and MPF were unable to differentiate patients with mesothelioma from patients with other malignancies or those presenting with transudative pleural effusions.
  • Combining the data from the three biomarkers using a logistic regression model did not improve sensitivity for detecting mesothelioma above that of the mesothelin marker alone.
  • CONCLUSION: Serum mesothelin remains the most specific marker for the diagnosis of mesothelioma.
  • [MeSH-major] Biomarkers, Tumor / blood. Membrane Glycoproteins / blood. Mesothelioma / blood. Osteopontin / blood. Pleural Neoplasms / blood

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670302.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 106441-73-0 / Osteopontin
  •  go-up   go-down


78. Barbieri PG, Somigliana A, Lombardi S, Girelli R, Benvenuti A: [Asbestos fibre lung burden and exposure indices in asbestos-cement workers]. Med Lav; 2009 Jan-Feb;100(1):21-8
Hazardous Substances Data Bank. AMOSITE ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Asbestos fibre lung burden and exposure indices in asbestos-cement workers].
  • BACKGROUND: In many previous studies, the asbestos fibres retained in the lung were regarded as a good index of cumulative occupational asbestos exposure.
  • Twelve workers suffering from asbestos-related diseases and had been employed in an asbestos-cement factory operating from 1961 to 1994 underwent post mortem investigations in the course of a criminal law suit.
  • OBJECTIVES: Samples of lung tissues were collected for electron microscopy analysis to measure the asbestos fibre burden of the lungs in workers with high exposure, and assess the possible correlation between asbestos fibre lung burden and the estimated levels of cumulative exposure.
  • METHODS: Samples of lung parenchyma obtained from a consecutive series of 12 post-mortem examinations that were performed between 1994 and 2007and included 5 cases of malignant pleural mesothelioma, 4 lung cancers, 1 case of asbestosis and2 ofpleuralplagues, were collected, stored and analysed by SEM electron microscopy, according to the methods suggested by the current scientific literature.
  • For each worker, all males, a detailed occupational history was reconstructed by means ofpersonal interviews; both the measurements of airborne asbestos fibresperformed by the factory in the 1970's and the duration of each single job in the plant were taken into account to estimate an individual cumulative exposure index.
  • RESULTS: A wide variation of total asbestos fibre concentrations in the lung (1,320-118 million) was observed; in all 12 workers, the lung amphibole fibre burden exceeded 1,000,000 fibres per g/dry tissue, The highest values were detected in the mesothelioma cases, in which the mean fibre concentrations differed statistically (t=2.29, p=0.045) from the mean calculated for the other asbestos-related diseases; in 9 subjects only amphibole fibres were detected.
  • There was a good correlation between total asbestos fibre concentration and cumulative exposure index (r=0.91, p<0.0001).
  • CONCLUSION: This study, which was numerically the biggest ever performed in Italy for this category of workers, confirms a wide range of total asbestos fibre burden in heavily occupationally exposed workers and showed that of the asbestos-related diseases, the highest lung concentrations of asbestos fibres were reached in cases of mesothelioma.
  • [MeSH-major] Asbestos, Amosite / analysis. Asbestos, Crocidolite / analysis. Construction Materials / adverse effects. Lung / chemistry. Occupational Diseases / etiology. Occupational Exposure / classification
  • [MeSH-minor] Aged. Asbestosis / etiology. Asbestosis / metabolism. Asbestosis / pathology. Electron Probe Microanalysis. Fibrosis. Humans. Italy. Lung Neoplasms / chemistry. Lung Neoplasms / etiology. Lung Neoplasms / ultrastructure. Male. Mesothelioma / chemistry. Mesothelioma / etiology. Mesothelioma / ultrastructure. Microscopy, Electron, Scanning. Middle Aged. Mineral Fibers / adverse effects. Occupations. Pleura / chemistry. Pleura / ultrastructure. Pleural Neoplasms / chemistry. Pleural Neoplasms / etiology. Pleural Neoplasms / ultrastructure

  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19263869.001).
  • [ISSN] 0025-7818
  • [Journal-full-title] La Medicina del lavoro
  • [ISO-abbreviation] Med Lav
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Mineral Fibers; 12001-28-4 / Asbestos, Crocidolite; 12172-73-5 / Asbestos, Amosite
  •  go-up   go-down


79. Aigner C, Hoda MA, Lang G, Taghavi S, Marta G, Klepetko W: Outcome after extrapleural pneumonectomy for malignant pleural mesothelioma. Eur J Cardiothorac Surg; 2008 Jul;34(1):204-7
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome after extrapleural pneumonectomy for malignant pleural mesothelioma.
  • BACKGROUND: Malignant pleural mesothelioma is a mainly asbestos-related neoplasm that occurs with increasing frequency and is associated with a poor prognosis.
  • We therefore analysed our experience with extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma.
  • METHODS: We retrospectively reviewed our institutional experience with all consecutive patients undergoing extrapleural pneumonectomy for malignant pleural mesothelioma from 1994 to 2005.
  • CONCLUSION: Extrapleural pneumonectomy as part of a multi-modality treatment regimen is a good treatment option for selected patients with malignant pleural mesothelioma.
  • [MeSH-major] Mesothelioma / surgery. Pleural Neoplasms / surgery. Pneumonectomy / methods

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18407510.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


80. Roggli VL: The role of analytical SEM in the determination of causation in malignant mesothelioma. Ultrastruct Pathol; 2006 Jan-Feb;30(1):31-5
Hazardous Substances Data Bank. AMOSITE ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of analytical SEM in the determination of causation in malignant mesothelioma.
  • The causative relationship between asbestos exposure and mesothelioma is firmly established.
  • The author has had the opportunity to study the lung asbestos content of 396 cases of mesothelioma, including 28 peritoneal cases, by means of analytical scanning electron microscopy.
  • Elevated tissue asbestos content was identified in 87% of pleural and 75% of peritoneal cases.
  • Peritoneal cases that are asbestos related have on average a higher lung fiber burden than pleural cases.
  • Mesotheliomas in women have elevated tissue asbestos content in about 60% of cases, and many of these had a history of exposure as a household contact of an asbestos worker.
  • [MeSH-major] Mesothelioma / ultrastructure. Microscopy, Electron, Scanning / methods. Peritoneal Neoplasms / ultrastructure. Pleural Neoplasms / ultrastructure
  • [MeSH-minor] Asbestos, Amosite / adverse effects. Asbestos, Amosite / analysis. Asbestos, Amosite / classification. Electron Probe Microanalysis. Female. Humans. Lung / ultrastructure. Peritoneum / ultrastructure. Pleura / ultrastructure

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16517468.001).
  • [ISSN] 1521-0758
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 12172-73-5 / Asbestos, Amosite
  •  go-up   go-down


81. Strand LA, Martinsen JI, Koefoed VF, Sommerfelt-Pettersen J, Grimsrud TK: Asbestos-related cancers among 28,300 military servicemen in the Royal Norwegian Navy. Am J Ind Med; 2010 Jan;53(1):64-71
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asbestos-related cancers among 28,300 military servicemen in the Royal Norwegian Navy.
  • INTRODUCTION: This study focus on the incidence of asbestos-related cancers among 28,300 officers and enlisted servicemen in the Royal Norwegian Navy.
  • Until 1987, asbestos aboard the vessels potentially caused exposure to 11,500 crew members.
  • METHODS: Standardized incidence ratios (SIR) were calculated for malignant mesothelioma, lung cancer, and laryngeal, pharyngeal, stomach, and colorectal cancers according to service aboard between 1950 and 1987 and in other Navy personnel.
  • RESULTS: Increased risk of mesothelioma was seen among engine room crews, with SIRs of 6.23 (95% CI = 2.51-12.8) and 6.49 (95% CI = 2.11-15.1) for personnel who served less than 2 years and those with longer service, respectively.
  • The mesothelioma incidence can be taken as an indicator of the presence or absence of asbestos exposure, but it offered no consistent explanation to the variation in incidence of other asbestos-related cancers.
  • [MeSH-major] Asbestos / adverse effects. Asbestosis / epidemiology. Military Personnel / statistics & numerical data. Naval Medicine / statistics & numerical data. Neoplasms / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Colorectal Neoplasms / epidemiology. Cross-Sectional Studies. Humans. Incidence. Laryngeal Neoplasms / epidemiology. Lung Neoplasms / pathology. Male. Mesothelioma / epidemiology. Middle Aged. Norway. Pharyngeal Neoplasms / epidemiology. Pleural Neoplasms / epidemiology. Risk Factors. Stomach Neoplasms / epidemiology. Young Adult

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Veterans and Military Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19921706.001).
  • [ISSN] 1097-0274
  • [Journal-full-title] American journal of industrial medicine
  • [ISO-abbreviation] Am. J. Ind. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


82. Petazzi A, Gaudiello F, Canti Z, Mensi C: [Cluster cases of malignant pleural mesothelioma in an oil factory]. Med Lav; 2005 Sep-Oct;96(5):440-4
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cluster cases of malignant pleural mesothelioma in an oil factory].
  • No cases are reported in literature of asbestos related disease in subjects who worked in oil factories.
  • Nevertheless the structure and organization of the workplace, which is similar to that of sugar refineries, where cases of malignant mesothelioma have been described (moreover in workers employed in running and maintenance of the plants), led to the assumption that even in oil factories asbestos for the insulation of pipes and boilers could be present.
  • OBJECTIVES: To describe 3 cases of Malignant Mesothelioma that occurred in workers of the same oil factory.
  • METHODS: Since this occupational sector is not conventionally known for asbestos exposure the Local Health Unit and the Lombardy Mesothelioma Registry decided to investigate this industrial plant.
  • RESULTS: Following examination of the archives of the Local Health Unit and inspection of the plant, an environmental asbestos contamination (pipes and boilers) was found.
  • This underlines the importance of close cooperation with Local Health Units of occupational medicine and the Regional Mesothelioma Registry in the study and acknowledgment of cases which would otherwise not have been recognized, with consequent loss of precious information.
  • [MeSH-major] Air Pollutants, Occupational / adverse effects. Asbestos / adverse effects. Chemical Industry. Mesothelioma / epidemiology. Occupational Diseases / epidemiology. Petroleum. Pleural Neoplasms / epidemiology


83. Marinaccio A, Scarselli A, Binazzi A, Altavista P, Belli S, Mastrantonio M, Pasetto R, Uccelli R, Comba P: Asbestos related diseases in Italy: an integrated approach to identify unexpected professional or environmental exposure risks at municipal level. Int Arch Occup Environ Health; 2008 Aug;81(8):993-1001
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asbestos related diseases in Italy: an integrated approach to identify unexpected professional or environmental exposure risks at municipal level.
  • PURPOSE: Past intensive use of asbestos has implied severe public health consequences.
  • Spatial distribution of deaths from malignant mesothelioma and of compensated cases for asbestos related diseases in Italy were compared to identify unexpected sources of asbestos exposure.
  • METHODS: Mortality for malignant mesothelioma at municipal level and geographical clusters of compensated cases for asbestos related diseases, as proxy of industrial asbestos exposure, were identified in the period 1988-2001.
  • RESULTS: Municipalities with at least four mesothelioma deaths and a statistically significant mortality excess were 148; and 53 out of them had no compensated case for asbestos-related diseases.
  • CONCLUSIONS: Availability long-term national figures and the different etiology of asbestos related diseases are the key features of this exercise that was applied to Italy, but can be replicated wherever registration systems of diseases related to long term exposure to asbestos are available.
  • [MeSH-major] Asbestos / poisoning. Environmental Exposure / analysis. Mesothelioma / epidemiology. Occupational Exposure / analysis. Pleural Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Ind Med. 1960 Oct;17:260-71 [13782506.001]
  • [Cites] Epidemiol Prev. 1999 Oct-Dec;23(4):316-26 [10730473.001]
  • [Cites] Br J Ind Med. 1965 Oct;22(4):261-9 [5836565.001]
  • [Cites] Lancet. 1981 May 2;1(8227):984-7 [6112395.001]
  • [Cites] Eur Respir J. 1996 Sep;9(9):1932-42 [8880114.001]
  • [Cites] J Natl Cancer Inst. 1979 Jul;63(1):17-22 [286826.001]
  • [Cites] Int J Occup Environ Health. 2005 Jan-Mar;11(1):36-44 [15859189.001]
  • [Cites] Tumori. 2002 Jul-Aug;88(4):266-9 [12400973.001]
  • [Cites] Eur J Epidemiol. 2000 May;16(5):411-7 [10997827.001]
  • [Cites] Br J Ind Med. 1993 Sep;50(9):779-84 [8398870.001]
  • [Cites] Med Lav. 1993 May-Jun;84(3):193-200 [8396198.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):666-72 [10027347.001]
  • [Cites] Epidemiol Prev. 2002 Nov-Dec;26(6):284-6 [12619492.001]
  • [Cites] Occup Environ Med. 2008 Mar;65(3):164-70 [17704197.001]
  • [Cites] Environ Health Perspect. 2007 Jul;115(7):1066-71 [17637924.001]
  • [Cites] Epidemiol Prev. 2006 Jan-Feb;30(1 Suppl 1):5-95 [16826748.001]
  • [Cites] Thorax. 1978 Apr;33(2):181-92 [663877.001]
  • [Cites] Am J Ind Med. 1992;21(5):681-7 [1609814.001]
  • [Cites] Eur J Cancer. 2003 Jun;39(9):1290-5 [12763219.001]
  • [Cites] Ann Ist Super Sanita. 2004;40(2):251-65 [15536279.001]
  • [Cites] Epidemiol Prev. 1989 Jun;11(39):29-34 [2533562.001]
  • [Cites] Med Lav. 2005 Jul-Aug;96(4):338-46 [16457430.001]
  • [Cites] Med Lav. 2002 Nov-Dec;93(6):507-18 [12596421.001]
  • [Cites] Epidemiol Prev. 1988 Dec;10(37):32-7 [2978855.001]
  • [Cites] Epidemiol Prev. 2004 Jul-Oct;28(4-5):239-46 [15732678.001]
  • [Cites] Am J Ind Med. 2002 Sep;42(3):188-99 [12210688.001]
  • [Cites] Rev Mal Respir. 1999 Dec;16(6 Pt 2):1294-307 [10897851.001]
  • [Cites] J Occup Med. 1992 Jul;34(7):718-21 [1494965.001]
  • [Cites] Eur J Cancer Prev. 1997 Apr;6(2):162-6 [9237066.001]
  • [Cites] Int J Cancer. 2005 May 20;115(1):142-7 [15645436.001]
  • [Cites] Br J Cancer. 2002 Jun 17;86(12):1970-1 [12085195.001]
  • [Cites] Scand J Work Environ Health. 1998 Aug;24(4):312-7 [9754864.001]
  • [Cites] Environ Health Perspect. 2001 Sep;109(9):915-9 [11673120.001]
  • [Cites] Int J Cancer. 1988 Apr 15;41(4):525-30 [3356487.001]
  • [Cites] Eur J Epidemiol. 1996 Aug;12(4):421-3 [8891549.001]
  • [Cites] Occup Environ Med. 1999 Aug;56(8):505-13 [10492646.001]
  • [Cites] Arch Environ Health. 2003 Apr;58(4):229-32 [14655903.001]
  • (PMID = 18094988.001).
  • [ISSN] 1432-1246
  • [Journal-full-title] International archives of occupational and environmental health
  • [ISO-abbreviation] Int Arch Occup Environ Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  •  go-up   go-down


84. Podobnik J, Kocijancic I, Kovac V, Sersa I: 3T MRI in evaluation of asbestos-related thoracic diseases - preliminary results. Radiol Oncol; 2010 Jun;44(2):92-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 3T MRI in evaluation of asbestos-related thoracic diseases - preliminary results.
  • The aim of this study was to evaluate the diagnostic potential of 3 T MRI as a complementary imaging modality to CT in detecting the pathological changes of asbestos-related thoracic diseases.
  • PATIENTS AND METHODS: Fifteen patients with the asbestos-related thoracic disease were scheduled for 3T MRI.
  • Five had a benign form of the disease and 10 had malignant pleural mesothelioma (MPM).
  • CONCLUSIONS: These preliminary results pointed out that MRI was equal or even better compared with CT examination for detecting possible malignant potential of pleural changes in the asbestos-related pleural disease, using signal intensity measurements of T2 fs-weighted images.
  • The 3T MRI enabled the accurate determination of chest pathology and it could be used for imaging of patients with the asbestos-related thoracic disease.
  • This finding turned us to propose 3T MRI imaging technique as a non-ionizing imaging method for the follow-up of patients with the isolated pleural form of the asbestos-related disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 1996 Apr;166(4):963-8 [8610582.001]
  • [Cites] Eur Respir J. 1998 Jan;11(1):194-7 [9543293.001]
  • [Cites] Eur J Radiol. 2000 Jun;34(3):196-207 [10927161.001]
  • [Cites] Acta Radiol. 2001 Sep;42(5):502-7 [11552888.001]
  • [Cites] Radiographics. 2004 Jan-Feb;24(1):105-19 [14730040.001]
  • [Cites] Invest Radiol. 2004 Sep;39(9):554-64 [15308938.001]
  • [Cites] Eur Radiol. 2005 Feb;15(2):324-8 [15565313.001]
  • [Cites] Radiology. 2008 Feb;246(2):596-604 [18056854.001]
  • [Cites] Invest Radiol. 2007 Jun;42(6):377-83 [17507808.001]
  • [Cites] AJR Am J Roentgenol. 2007 Aug;189(2):386-92 [17646465.001]
  • (PMID = 22933897.001).
  • [ISSN] 1318-2099
  • [Journal-full-title] Radiology and oncology
  • [ISO-abbreviation] Radiol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovenia
  • [Other-IDs] NLM/ PMC3423685
  • [Keywords] NOTNLM ; 3T, magnetic resonance imaging / asbestos-related thoracic disease / malignant pleural mesothelioma
  •  go-up   go-down


85. Rezaei Kalantari H: [Malignant peritoneal mesothelioma: a case report]. Rev Med Liege; 2010 Sep;65(9):490-2
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant peritoneal mesothelioma: a case report].
  • I report two cases of malignant peritoneal mesothelioma.
  • Mesothelioma is mostly a pleural disease whether visceral or parietal.
  • Infra-diaphragmatic Mesothelioma accounts for only 10-20% of all mesotheliomas.
  • In over 80% of the cases the pathogenesis is related to asbestos and radiation exposure.
  • One of our two patients has non past history of exposure to asbestos.
  • Prognosis for patients with malignant peritoneal mesothelioma is very poor with a mean survival of 5,4 months versus 12.5 months for pleural mesothelioma.
  • Peritoneal mesothelioma, although rare, should be considered among the differential diagnosis of ascites differential diagnosis work up.
  • [MeSH-major] Mesothelioma / diagnosis. Peritoneal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21086578.001).
  • [ISSN] 0370-629X
  • [Journal-full-title] Revue médicale de Liège
  • [ISO-abbreviation] Rev Med Liege
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


86. Goudar RK: Management options for malignant pleural mesothelioma: clinical and cost considerations. Drugs; 2007;67(8):1149-65
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management options for malignant pleural mesothelioma: clinical and cost considerations.
  • Malignant pleural mesothelioma (MPM) is a resistant form of lung cancer that is often related to prior asbestos exposure.
  • [MeSH-major] Mesothelioma / economics. Mesothelioma / therapy. Pleural Neoplasms / economics. Pleural Neoplasms / therapy

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 1995 Sep;108(3):754-8 [7656629.001]
  • [Cites] Br J Cancer. 2003 Jun 16;88(12):1839-43 [12799624.001]
  • [Cites] Eur Respir J. 1991 Jan;4(1):76-83 [1902799.001]
  • [Cites] Eur J Cancer. 1995 Jun;31A(6):981-6 [7646933.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Thorax. 2001 Apr;56(4):250-65 [11254815.001]
  • [Cites] Clin Lung Cancer. 2006 Jan;7(4):257-61 [16512979.001]
  • [Cites] Mol Cancer Ther. 2002 May;1(7):545-52 [12479273.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S117-21 [15950791.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):274-81 [11773179.001]
  • [Cites] J Thorac Cardiovasc Surg. 1991 Jul;102(1):1-9 [2072706.001]
  • [Cites] J Thorac Cardiovasc Surg. 2004 Jul;128(1):138-46 [15224033.001]
  • [Cites] Am J Clin Oncol. 2005 Jun;28(3):223-6 [15923792.001]
  • [Cites] Thorax. 1999 Mar;54(3):238-41 [10325900.001]
  • [Cites] Eur J Cardiothorac Surg. 2005 Mar;27(3):373-8 [15740941.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Feb 1;43(3):511-6 [10078630.001]
  • [Cites] Chest. 2004 Oct;126(4):1318-29 [15486399.001]
  • [Cites] Occup Environ Med. 2004 May;61(5):438-41 [15090665.001]
  • [Cites] Oncology (Williston Park). 2004 Nov;18(13 Suppl 8):26-31 [15655933.001]
  • [Cites] Ann Oncol. 2005 Jun;16(6):923-7 [15824080.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):655; author reply 655 [15659523.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Dec;19(6):1117-36, vii [16325127.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Jan;59(1):149-50 [16636799.001]
  • [Cites] Ann Oncol. 2005 Mar;16(3):345-51 [15677623.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5 [9869758.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Oct;122(4):788-95 [11581615.001]
  • [Cites] Radiother Oncol. 2006 Jul;80(1):13-8 [16820238.001]
  • [Cites] Br J Cancer. 2004 Jul 5;91(1):9-10 [15199394.001]
  • [Cites] Chest. 2001 Oct;120(4):1167-74 [11591556.001]
  • [Cites] Ann Surg Oncol. 1997 Dec;4(8):628-33 [9416409.001]
  • [Cites] Lung Cancer. 2005 Jun;48(3):429-34 [15893013.001]
  • [Cites] Ann Thorac Surg. 1999 Nov;68(5):1799-804 [10585061.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):349-54 [12525529.001]
  • [Cites] Lung Cancer. 2005 May;48(2):291-6 [15829331.001]
  • [Cites] Chest. 2003 Feb;123(2):551-61 [12576380.001]
  • [Cites] Ann Oncol. 2005;16 Suppl 2:ii240-5 [15958465.001]
  • [Cites] Lung Cancer. 2005 Oct;50(1):83-6 [15951053.001]
  • [Cites] Curr Oncol Rep. 2005 Jul;7(4):260-5 [15946584.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):6881-9 [16192580.001]
  • [Cites] In Vivo. 2000 Jan-Feb;14(1):93-100 [10757064.001]
  • [Cites] Lung Cancer. 2004 May;44(2):251-9 [15084390.001]
  • [Cites] Eur J Cancer. 2003 Feb;39(3):353-7 [12565988.001]
  • [Cites] J Clin Oncol. 2000 Dec 1;18(23):3912-7 [11099320.001]
  • [Cites] Thorax. 2003 Feb;58(2):96-7 [12554885.001]
  • [Cites] Med Dosim. 2002 Winter;27(4):255-9 [12521069.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Dec;19(6):1089-97, vii [16325125.001]
  • [Cites] Photochem Photobiol. 2003 Jul;78(1):75-81 [12929752.001]
  • [Cites] Lung Cancer. 2005 Oct;50(1):75-82 [16005104.001]
  • [Cites] Am J Pathol. 1993 May;142(5):1524-33 [8388174.001]
  • [Cites] Chest. 1998 Mar;113(3):723-31 [9515850.001]
  • [Cites] Ann Thorac Surg. 2003 Mar;75(3):952-9 [12645723.001]
  • [Cites] Thorax. 2004 Feb;59(2):144-8 [14760156.001]
  • [Cites] Thorac Surg Clin. 2004 Nov;14(4):543-8 [15559061.001]
  • [Cites] J Clin Oncol. 1999 Jan;17 (1):25-30 [10458214.001]
  • [Cites] Lung Cancer. 2005 May;48(2):157-69 [15829316.001]
  • [Cites] Ann Thorac Surg. 2004 Jul;78(1):245-52 [15223437.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1435-42 [16446322.001]
  • [Cites] Br J Cancer. 2002 Feb 1;86(3):342-5 [11875695.001]
  • [Cites] Ann Thorac Surg. 1997 Feb;63(2):334-8 [9033296.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1443-8 [16549838.001]
  • [Cites] Cochrane Database Syst Rev. 2006 Jul 19;(3):CD003880 [16856023.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1591-603 [16221782.001]
  • [Cites] Thorac Surg Clin. 2004 Nov;14(4):549-56 [15559062.001]
  • [Cites] Lancet. 2005 Jul 30-Aug 5;366(9483):397-408 [16054941.001]
  • [Cites] J Thorac Oncol. 2006 Jul;1(6):591-601 [17409924.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7444-53 [16243818.001]
  • [Cites] Ann Oncol. 2004 Feb;15(2):257-60 [14760119.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Dec;19(6):1099-115, vii [16325126.001]
  • [Cites] Lung Cancer. 2002 Nov;38(2):111-21 [12399121.001]
  • [Cites] Clin Chest Med. 2006 Jun;27(2):335-54 [16716822.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Lung Cancer. 2005 Jun;48(3):423-8 [15893012.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1406-12 [15319247.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1031-9 [16616487.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3007-12 [16809726.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):982-92 [15709163.001]
  • [Cites] Cancer Invest. 2005;23 (7):643-50 [16305992.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3451-7 [15337794.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):606-16 [12573747.001]
  • [Cites] Curr Probl Cancer. 2004 May-Jun;28(3):93-174 [15197388.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Dec;19(6):1147-73, viii [16325129.001]
  • [Cites] Am J Clin Oncol. 1990 Feb;13(1):4-9 [1689538.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):145-52 [9440736.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2300-4 [15788680.001]
  • [Cites] Curr Opin Oncol. 2003 Mar;15(2):144-7 [12601279.001]
  • [Cites] Cancer. 2007 Jan 1;109 (1):93-9 [17146783.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Jan;29(1):14-9 [16343925.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Dec;19(6):1137-45, viii [16325128.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1561-7 [16575008.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3495-501 [15908659.001]
  • [Cites] Thorac Surg Clin. 2004 Nov;14(4):531-42 [15559060.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):640-5 [16751058.001]
  • (PMID = 17521217.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Number-of-references] 102
  •  go-up   go-down


87. Park EK, Hannaford-Turner KM, Hyland RA, Johnson AR, Yates DH: Asbestos-related occupational lung diseases in NSW, Australia and potential exposure of the general population. Ind Health; 2008 Dec;46(6):535-40
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asbestos-related occupational lung diseases in NSW, Australia and potential exposure of the general population.
  • Asbestos is a fibrous silicate which is recognized as causing a variety of lung disorders including malignant mesothelioma of the pleura, lung cancer and asbestosis.
  • Asbestos use has been banned in most developed countries but exposure still occurs under strict regulation in occupational settings and also occasionally in domestic settings.
  • Although the hazards of asbestos are well known in developed countries, awareness of its adverse health effects is less in other parts of the world, particularly when exposure occurs in non-occupational settings.
  • Experience of asbestos use and its adverse heath effects in developed countries such as Australia have resulted in development of expertise in the diagnosis and treatment of asbestos-related diseases as well as in screening and this can be used to help developing countries facing the issue of asbestos exposure.
  • [MeSH-major] Asbestos / adverse effects. Lung Diseases. Occupational Exposure. Public Health
  • [MeSH-minor] Humans. Mesothelioma / etiology. New South Wales. Risk Assessment

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19088405.001).
  • [ISSN] 1880-8026
  • [Journal-full-title] Industrial health
  • [ISO-abbreviation] Ind Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 1332-21-4 / Asbestos
  • [Number-of-references] 43
  •  go-up   go-down


88. Le Neindre B, Bouvier V, Galateau-Sallé F, de Quillacq A, Launoy G, Letourneux M: [Compensation of malignant mesothelioma as an occupational disease in Lower Normandy, from 1995 to 2002]. Rev Epidemiol Sante Publique; 2007 Apr;55(2):123-31
MedlinePlus Health Information. consumer health - Occupational Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Compensation of malignant mesothelioma as an occupational disease in Lower Normandy, from 1995 to 2002].
  • BACKGROUND: Despite the close relation between occupational exposure to asbestos and malignant mesothelioma, the compensation of this disease is still far from being the rule.
  • The objective of this study is to assess the compensation process of all the cases of occupational mesothelioma recorded by the regional mesothelioma registry between September 1995 and August 2002, and to make suggestions for improvement of the compensation of future cases.
  • METHODS: Lifetime exposure to asbestos was assessed for each of the 141 mesothelioma cases observed in Lower Normandy during this time period, and 105 cases could be related to a possible, probable, or very probable occupational exposure to this mineral.
  • RESULTS: Except for five cases in which insurance conditions did not allow any compensation, compensation of occupational mesothelioma occurred in 85% of the cases.
  • This high rate was probably the result of the existence of an early asbestos industry in this region, and of the particular awareness of the Norman population about asbestos-related diseases, as well as of the epidemiological follow-up of mesothelioma in Lower Normandy.
  • CONCLUSION: In order to improve the rate of compensation of occupational malignant mesothelioma cases, information about the usual occupational origin of the disease should be delivered systematically to the general practitioner of each patient.
  • This could be done by pathologists, when they diagnose malignant mesothelioma, and/or by medical examiners when sickness benefits are sought, or even by the epidemiological center of death causes (INSERM, CépiDc), for the beneficiaries of patients who died from malignant mesothelioma.
  • [MeSH-major] Compensation and Redress. Lung Neoplasms / economics. Mesothelioma / economics. Occupational Diseases / economics

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17442515.001).
  • [ISSN] 0398-7620
  • [Journal-full-title] Revue d'épidémiologie et de santé publique
  • [ISO-abbreviation] Rev Epidemiol Sante Publique
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


89. De Bruin ML, Burgers JA, Baas P, van 't Veer MB, Noordijk EM, Louwman MW, Zijlstra JM, van den Berg H, Aleman BM, van Leeuwen FE: Malignant mesothelioma after radiation treatment for Hodgkin lymphoma. Blood; 2009 Apr 16;113(16):3679-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mesothelioma after radiation treatment for Hodgkin lymphoma.
  • Malignant mesothelioma is a relatively uncommon malignancy.
  • Although the pathogenesis is primarily related to asbestos, the disease may be associated with radiation exposure.
  • Recently, increased risks for second primary mesothelioma after radiation for lymphoma have been reported.
  • We examined mesothelioma risk in 2567 5-year survivors of Hodgkin lymphoma.
  • Although histology and survival of the mesothelioma cases were comparable with cases from the general population, asbestos exposure and the proportion of males were lower than expected.
  • The evidence for radiotherapy as cause for mesothelioma independent of exposure to asbestos is expanding, and the diagnosis of mesothelioma should be kept in mind whenever related symptoms arise in patients who had previous irradiation.
  • [MeSH-major] Hodgkin Disease / mortality. Hodgkin Disease / radiotherapy. Mesothelioma / mortality. Neoplasms, Radiation-Induced / mortality


90. Musk AW, Olsen NJ, Reid A, Threlfall T, de Klerk NH: Asbestos-related disease from recycled hessian superphosphate bags in rural Western Australia. Aust N Z J Public Health; 2006 Aug;30(4):312-3
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Asbestos-related disease from recycled hessian superphosphate bags in rural Western Australia.
  • OBJECTIVES: To describe the dissemination of asbestos fibres within the Western Australian community.
  • On questioning, she recalled exposure to asbestos as a child on the family farm.
  • Her mother died from malignant pleural mesothelioma.
  • It is possible that many farmers and their families have had similar exposure to asbestos.
  • IMPLICATIONS: The risk of developing an asbestos-related disease is not restricted to any specific social or employment groups within the Australian community.
  • [MeSH-major] Asbestos / adverse effects. Diphosphates. Fertilizers. Product Packaging

  • MedlinePlus Health Information. consumer health - Asbestos.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16956157.001).
  • [ISSN] 1326-0200
  • [Journal-full-title] Australian and New Zealand journal of public health
  • [ISO-abbreviation] Aust N Z J Public Health
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Diphosphates; 0 / Fertilizers; 1332-21-4 / Asbestos; 8011-76-5 / superphosphate
  •  go-up   go-down


91. Chee J, Singh J, Naran A, Misso NL, Thompson PJ, Bhoola KD: Novel expression of kallikreins, kallikrein-related peptidases and kinin receptors in human pleural mesothelioma. Biol Chem; 2007 Nov;388(11):1235-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel expression of kallikreins, kallikrein-related peptidases and kinin receptors in human pleural mesothelioma.
  • Malignant mesothelioma is an aggressive cancer of the pleura that is causally related to exposure to asbestos fibres.
  • The kallikrein serine proteases [tissue (hK1) and plasma (hKB1) kallikreins, and kallikrein-related peptidases (KRP/hK2-15)] and the mitogenic kinin peptides may have a role in tumourigenesis.
  • The expression of hK1, hKB1, KRP/hK2, 5, 6, 7, 8 and 9, and kinin B(1) and B(2) receptors was assessed in archived selected normal tissue and mesothelioma tumour sections by immunoperoxidase and immunofluorescence labelling. hK1, hKB1 and kinin B(1) and B(2) receptors were expressed in malignant cells of the epithelioid and sarcomatoid components of biphasic mesothelioma tumour cells.
  • KRP/hK2, 6, 8 and 9 were also expressed in the cytoplasm and nuclei of mesothelioma cells, whereas KRP/hK5 and hK7 showed predominantly cytoplasmic localisation.
  • This is a first report, but further studies are required to determine whether these proteins have a functional role in the pathogenesis of mesothelioma and/or may be potential biomarkers for pleural mesothelioma.
  • [MeSH-major] Kallikreins / metabolism. Kinins / metabolism. Mesothelioma / metabolism. Peptide Hydrolases / metabolism. Pleural Neoplasms / metabolism. Receptors, Cell Surface / metabolism

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17976017.001).
  • [ISSN] 1431-6730
  • [Journal-full-title] Biological chemistry
  • [ISO-abbreviation] Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Kinins; 0 / Receptors, Cell Surface; EC 3.4.- / Peptide Hydrolases; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


92. Usami N, Fukui T, Kondo M, Taniguchi T, Yokoyama T, Mori S, Yokoi K, Horio Y, Shimokata K, Sekido Y, Hida T: Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci; 2006 May;97(5):387-94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients.
  • Malignant pleural mesothelioma (MPM) is an asbestos-related malignancy that is highly resistant to current therapeutic modalities.
  • [MeSH-major] Cell Line, Tumor. Mesothelioma / pathology. Pleural Neoplasms / pathology


93. Pesatori AC, Mensi C: Peculiar features of mesothelioma occurrence as related to exposure patterns and circumstances in the Lombard Region, Italy. Med Lav; 2005 Jul-Aug;96(4):354-9
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peculiar features of mesothelioma occurrence as related to exposure patterns and circumstances in the Lombard Region, Italy.
  • BACKGROUND: The "Lombardy Mesothelioma Registry" started its activity in 2000 in accordance with Italian law DL 277/91.
  • OBJECTIVES AND METHODS: The Registry collects all new incident cases of Malignant Mesothelioma (MM) of pleura, peritoneum, pericardium and vaginal tunic of testis occurring in residents in the Lombardy Region (Northern Italy).
  • For confirmed cases, a standardized questionnaire is administered to the subject or next-of-kin, to verify sources of lifetime asbestos exposure.
  • 21 were peritoneal mesothelioma.
  • Standardized rates for pleural mesothelioma were respectively 3.7 and 1.4 per 100,000 for males and females.
  • Occupational asbestos exposure was ascertained for 71% of male cases and 26% of females.
  • The main relevant exposures were in building trades, metal manufacturing, machine production and maintenance; an unexpectedly high proportion of female cases was engaged in non-asbestos textile factories.
  • CONCLUSIONS: The high proportion of cases with unknown exposure underlines the need to explore new tools and sources to ascertain asbestos exposure.
  • An ad hoc survey in textile industries showed exposure to asbestos to be widely spread in this industry.
  • [MeSH-major] Mesothelioma / diagnosis. Occupational Diseases / diagnosis. Peritoneal Neoplasms / diagnosis. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Asbestos / adverse effects. Carcinogens / toxicity. Female. Humans. Incidence. Italy / epidemiology. Male. Middle Aged. Occupational Exposure / adverse effects. Registries. Retrospective Studies. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16457432.001).
  • [ISSN] 0025-7818
  • [Journal-full-title] La Medicina del lavoro
  • [ISO-abbreviation] Med Lav
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Carcinogens; 1332-21-4 / Asbestos
  •  go-up   go-down


94. Edwards JG, Swinson DE, Jones JL, Waller DA, O'Byrne KJ: EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer; 2006 Dec;54(3):399-407
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma.
  • Malignant mesothelioma (MM) is a fatal tumour of increasing incidence which is related to asbestos exposure.
  • [MeSH-major] Biomarkers, Tumor / analysis. Mesothelioma / mortality. Pleural Neoplasms / mortality. Receptor, Epidermal Growth Factor / analysis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17049671.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


95. Wilczyńska U, Szymczak W, Szeszenia-Dabrowska N: Mortality from malignant neoplasms among workers of an asbestos processing plant in Poland: results of prolonged observation. Int J Occup Med Environ Health; 2005;18(4):313-26
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mortality from malignant neoplasms among workers of an asbestos processing plant in Poland: results of prolonged observation.
  • OBJECTIVES: The study on mortality from cancer among workers of an asbestos plant manufacturing asbestos yarn, cloth, cords, packings, stuffing, brake linings and asbestos-rubber sheets was launched in the 1980s.
  • The present paper discusses the results of further tracing of asbestos workers of the same plant.
  • MATERIALS AND METHODS: The study cohort covered 4497 workers employed at the asbestos plant in 1945-1980.
  • Mortality from malignant neoplasms in total (281 deaths among men, SMR = 118, 95%CI: 105-133 and 135 deaths among women, SMR = 159, 95%CI: 133-188) as well as that from lung cancer (102 deaths among men, SMR = 126, 95%CI: 103-153 and 18 deaths among women, SMR = 259, 95%CI: 153-409) were significantly higher than in the general population.
  • Unlike earlier stages of analysis, the present study revealed an increased risk of pleural mesothelioma (2 deaths among men, SMR = 510, 95%CI: 62-1842 and 3 deaths among women, SMR = 2033, 95%CI: 419-5941).
  • Mortality analysis among workers with asbestosis and in those without diagnosed asbestosis, did not reveal direct association between the risk of asbestos-induced lung cancer and previously diagnosed asbestosis.
  • CONCLUSIONS: The prolonged cohort tracing showed an increased risk of asbestos-related cancers.
  • [MeSH-major] Asbestos / adverse effects. Mesothelioma / mortality

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16617847.001).
  • [ISSN] 1232-1087
  • [Journal-full-title] International journal of occupational medicine and environmental health
  • [ISO-abbreviation] Int J Occup Med Environ Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Air Pollutants, Occupational; 1332-21-4 / Asbestos
  •  go-up   go-down


96. Gaafar R, Bahnassy A, Abdelsalam I, Kamel MM, Helal A, Abdel-Hamid A, Eldin NA, Mokhtar N: Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma. Lung Cancer; 2010 Oct;70(1):43-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma.
  • BACKGROUND: Malignant pleural mesothelioma (MPM) is an asbestos related aggressive tumor.
  • Asbestos causes genetic modifications and cell signaling events that favor resistance to chemotherapy.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Mesothelioma / enzymology. Pleural Neoplasms / enzymology. Receptor, Epidermal Growth Factor / biosynthesis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20347505.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


97. Murakami S, Nishimura Y, Maeda M, Kumagai N, Hayashi H, Chen Y, Kusaka M, Kishimoto T, Otsuki T: Cytokine alteration and speculated immunological pathophysiology in silicosis and asbestos-related diseases. Environ Health Prev Med; 2009 Jul;14(4):216-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine alteration and speculated immunological pathophysiology in silicosis and asbestos-related diseases.
  • This review is partly composed of the presentation "Cytokine alteration and speculated immunological pathophysiology in silicosis and asbestos-related diseases" delivered during the symposium "Biological effects of fibrous and particulate substances and related areas" organized by the Study Group of Fibrous and Particulate Studies of the Japanese Society of Hygiene and held at the 78th Annual Meeting in Kumamoto, Japan.
  • In this review, we briefly introduce the results of recent immunological analysis using the plasma of silica and asbestos-exposed patients diagnosed with silicosis, pleural plaque, or malignant mesothelioma.
  • Thereafter, experimental background and speculation concerning the immunological pathophysiology of silica and asbestos-exposed patients are discussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Immunol. 1999 Dec;118(3):441-4 [10594565.001]
  • [Cites] Am J Respir Cell Mol Biol. 1995 May;12(5):455-60 [7742009.001]
  • [Cites] Int J Immunopathol Pharmacol. 2006 Apr-Jun;19(2):357-68 [16831302.001]
  • [Cites] Semin Cancer Biol. 2007 Aug;17(4):299-308 [17656106.001]
  • [Cites] Apoptosis. 2006 Oct;11(10):1825-35 [16850164.001]
  • [Cites] Exp Biol Med (Maywood). 2006 May;231(5):522-33 [16636300.001]
  • [Cites] Autoimmun Rev. 2008 May;7(5):370-5 [18486924.001]
  • [Cites] Clin Exp Pharmacol Physiol. 2006 May-Jun;33(5-6):519-24 [16700888.001]
  • [Cites] Scand J Immunol. 2005 May;61(5):442-8 [15882436.001]
  • [Cites] Immunol Lett. 2005 Apr 15;98(1):145-52 [15790520.001]
  • [Cites] Environ Int. 2008 Aug;34(6):765-72 [18295333.001]
  • [Cites] Environ Health Prev Med. 2007 Jul;12(4):151-2 [21432057.001]
  • [Cites] Adv Immunol. 2003;81:331-71 [14711059.001]
  • [Cites] Environ Health Prev Med. 2008 Mar;13(2):55-9 [19568881.001]
  • [Cites] Int J Mol Med. 1999 Oct;4(4):407-11 [10493983.001]
  • [Cites] Int J Clin Lab Res. 1991;21(2):152-8 [1687725.001]
  • [Cites] Clin Rev Allergy Immunol. 2005 Jun;28(3):187-96 [16129903.001]
  • [Cites] Crit Rev Immunol. 2007;27(6):511-25 [18197797.001]
  • [Cites] Environ Health Prev Med. 2008 Mar;13(2):53-4 [19568880.001]
  • [Cites] Int J Hematol. 2006 Jul;84(1):63-9 [16867905.001]
  • [Cites] Am J Ind Med. 1995 Nov;28(5):603-8 [8561170.001]
  • [Cites] Immunology. 1998 Jun;94(2):258-62 [9741350.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5137-44 [11431352.001]
  • [Cites] Clin Med Circ Respirat Pulm Med. 2008 Mar 26;2:11-7 [21157517.001]
  • [Cites] Proc R Soc Med. 1959 Dec;52:1111-3 [13807528.001]
  • [Cites] Immunol Res. 2008;40(1):18-34 [18193361.001]
  • [Cites] Cell Mol Immunol. 2007 Aug;4(4):261-8 [17764616.001]
  • [Cites] Thorac Surg Clin. 2004 Nov;14(4):479-87 [15559054.001]
  • [Cites] Nat Immunol. 2008 May;9(5):503-10 [18425107.001]
  • [Cites] Nature. 1981 Dec 24;294(5843):770-1 [6275274.001]
  • [Cites] Immunol Lett. 2000 May 1;72(2):137-43 [10841950.001]
  • [Cites] Immunol Res. 2006;36(1-3):137-46 [17337774.001]
  • [Cites] Environ Health Prev Med. 2007 Jul;12(4):153-60 [21432058.001]
  • [Cites] Crit Rev Toxicol. 1982 Oct;10(4):303-19 [6293769.001]
  • [Cites] Monaldi Arch Chest Dis. 1998 Apr;53(2):160-7 [9689803.001]
  • [Cites] Eur J Cancer. 2005 Nov;41(16):2502-12 [16199153.001]
  • [Cites] Cell. 2008 May 30;133(5):775-87 [18510923.001]
  • [Cites] J Occup Med. 1992 Jul;34(7):718-21 [1494965.001]
  • [Cites] Cancer Sci. 2008 Jan;99(1):98-106 [17970785.001]
  • [Cites] Am Fam Physician. 2007 Mar 1;75(5):683-8 [17375514.001]
  • [Cites] Eur J Haematol. 2008 Sep;81(3):209-17 [18510697.001]
  • [Cites] Int Immunol. 2006 Feb;18(2):269-77 [16361311.001]
  • [Cites] Free Radic Biol Med. 1992;12(4):293-315 [1577332.001]
  • [Cites] Clin Exp Immunol. 1997 Nov;110(2):303-9 [9367417.001]
  • [Cites] Breast Cancer. 2000;7(2):124-9 [11029783.001]
  • [Cites] J Cell Biochem Suppl. 1996;24:142-51 [8806096.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):316-26 [12538484.001]
  • [Cites] Ann Intern Med. 1961 Oct;55:667-72 [14475979.001]
  • [Cites] Thorax. 1962 Sep;17:205-12 [13876317.001]
  • [Cites] Thorax. 1995 Aug;50(8):887-93 [7570443.001]
  • [Cites] Regul Toxicol Pharmacol. 1991 Apr;13(2):133-49 [1852926.001]
  • [Cites] Immunol Rev. 2006 Aug;212:28-50 [16903904.001]
  • [Cites] Clin Microbiol Rev. 1996 Oct;9(4):532-62 [8894351.001]
  • [Cites] J Occup Environ Med. 2000 Jan;42(1):19-24 [10652684.001]
  • [Cites] Immunol Res. 1998;18(3):125-73 [9951648.001]
  • [Cites] Environ Health Perspect. 1997 Sep;105 Suppl 5:1165-71 [9400718.001]
  • [Cites] Trends Immunol. 2007 Nov;28(11):491-6 [17964217.001]
  • (PMID = 19568841.001).
  • [ISSN] 1342-078X
  • [Journal-full-title] Environmental health and preventive medicine
  • [ISO-abbreviation] Environ Health Prev Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2711881
  •  go-up   go-down


98. Musk AW, de Klerk NH, Reid A, Ambrosini GL, Fritschi L, Olsen NJ, Merler E, Hobbs MS, Berry G: Mortality of former crocidolite (blue asbestos) miners and millers at Wittenoom. Occup Environ Med; 2008 Aug;65(8):541-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mortality of former crocidolite (blue asbestos) miners and millers at Wittenoom.
  • BACKGROUND: Blue asbestos was mined and milled at Wittenoom in Western Australia between 1943 and 1966.
  • Person-years at risk were derived using two censoring dates in order to produce minimum and maximum estimates of asbestos effect.
  • RESULTS: There have been 190 cases of pleural and 32 cases of peritoneal mesothelioma in this cohort of former workers at Wittenoom.
  • CONCLUSION: Asbestos related diseases, particularly malignant mesothelioma, lung cancer and pneumoconiosis, continue to be the main causes of excess mortality in the former blue asbestos miners and millers of Wittenoom.
  • [MeSH-major] Asbestos, Crocidolite / toxicity. Mesothelioma / mortality. Mining. Occupational Exposure / adverse effects. Peritoneal Neoplasms / mortality. Respiratory Tract Diseases / mortality

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18045848.001).
  • [ISSN] 1470-7926
  • [Journal-full-title] Occupational and environmental medicine
  • [ISO-abbreviation] Occup Environ Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 12001-28-4 / Asbestos, Crocidolite
  •  go-up   go-down


99. Ray M, Kindler HL: Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest; 2009 Sep;136(3):888-896
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant pleural mesothelioma: an update on biomarkers and treatment.
  • Although the insulating properties of asbestos have been known for millennia, the link between asbestos exposure and mesothelioma was not recognized until 1960, when it was first described in South African asbestos miners.
  • The incidence of mesothelioma parallels asbestos usage with a latency of 20 to 40+ years; thus, patient numbers are declining in the United States but rising in the developing world.
  • Newly described biomarkers, including soluble mesothelin-related peptide, megakaryocyte potentiation factor, and osteopontin, may predict which asbestos-exposed individuals will develop mesothelioma, and may prove useful in assessing response to treatment.
  • This combination improves response, survival, time to progression, pulmonary function, and disease-related symptoms.
  • As we learn more about mesothelioma biology, molecularly targeted agents may become treatment options.
  • [MeSH-major] Biomarkers, Tumor / analysis. Mesothelioma / therapy. Pleural Neoplasms / therapy


100. Cristaudo A, Foddis R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, Canessa PA, Chella A, Lucchi M, Mussi A, Mutti L: Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma. Int J Biol Markers; 2010 Jul-Sep;25(3):164-70
Hazardous Substances Data Bank. ASBESTOS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma.
  • BACKGROUND: A potential role of serum osteopontin (OPN) and serum mesothelin-related peptide (SMRP) in the diagnosis of malignant pleural mesothelioma (MPM) has been recently reported.
  • Our study aimed to evaluate the influence of preanalytic variables on serum and plasma OPN, to compare serum and plasma OPN in the same population, and to assess whether OPN levels can aid in the diagnostic distinction of patients with MPM versus benign respiratory disease (BRD) and healthy subjects exposed to asbestos.
  • We measured OPN in 239 plasma samples from 207 asbestos-exposed subjects including 94 healthy controls and 113 subjects with BRD, and 32 patients with epithelial MPM, employing a commercially available ELISA.
  • Within the control group no significant correlation was observed between age, duration of asbestos exposure, pack-years in current smokers, lung function or imaging parameters and plasma or serum OPN.
  • CONCLUSIONS: These data suggest that plasma OPN and serum OPN are not influenced by confounding factors such as age, smoking habits and asbestos exposure.
  • [MeSH-major] Asbestos / adverse effects. Biomarkers, Tumor / blood. Mesothelioma / blood. Osteopontin / blood. Pleural Neoplasms / blood. Specimen Handling

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Biospecimen Research Database. Biospecimen Research Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20878622.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 106441-73-0 / Osteopontin; 1332-21-4 / Asbestos
  •  go-up   go-down






Advertisement